<!-- This content is only licensed for consumption by authorized users affiliated with PubMed Central. Usage by any individual not directly associated with PubMed Central is prohibited. -->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" id="b915423638" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id><journal-id journal-id-type="publisher-id">cn</journal-id><journal-id journal-id-type="coden">acncdm</journal-id><journal-title-group><journal-title>ACS Chemical Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1948-7193</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher><self-uri>pubs.acs.org/chemneuro</self-uri></journal-meta>
<article-meta><article-id pub-id-type="pmid">40304428</article-id><article-id pub-id-type="pmc">PMC12100659</article-id>
<article-id pub-id-type="doi">10.1021/acschemneuro.4c00883</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Role of &#x003b1;&#x02011;Synuclein&#x02013;DNAJB6b
Coaggregation in Amyloid Suppression</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5391687</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8380-4650</contrib-id><name><surname>P&#x000e1;lmad&#x000f3;ttir</surname><given-names>Tinna</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7400221</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-5096-8315</contrib-id><name><surname>Getachew</surname><given-names>Josef</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3359772</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6171-9703</contrib-id><name><surname>Thacker</surname><given-names>Dev</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7399881</contrib-id><name><surname>Wallerstein</surname><given-names>Johan</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">143417</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2200-1605</contrib-id><name><surname>Olsson</surname><given-names>Ulf</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1547618</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8762-477X</contrib-id><name><surname>Emanuelsson</surname><given-names>Cecilia</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1107880</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9629-7109</contrib-id><name><surname>Linse</surname><given-names>Sara</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#x02020;</label>
<institution content-type="dept">Biochemistry
and Structural Biology</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">5193</institution-id><institution>Lund University</institution></institution-wrap>, <postal-code>22100</postal-code>
<city>Lund</city>, <country country="SE">Sweden</country>
</aff><aff id="aff2">
<label>&#x02021;</label>
<institution content-type="dept">Biophysical
Chemistry</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">90825</institution-id><institution>Lund University</institution></institution-wrap>, <postal-code>22100</postal-code>
<city>Lund</city>, <country country="SE">Sweden</country>
</aff><aff id="aff3">
<label>&#x000a7;</label>
<institution content-type="dept">Physical
Chemistry</institution>, <institution>Lund University</institution>, <postal-code>22100</postal-code>
<city>Lund</city>, <country country="SE">Sweden</country>
</aff></contrib-group><author-notes><corresp id="cor1">
<label>*</label>Email: <email>tinna.palmadottir@biochemistry.lu.se</email>.</corresp><corresp id="cor2">
<label>*</label>Email: <email>sara.linse@biochemistry.lu.se</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>21</day><month>5</month><year>2025</year></pub-date><volume>16</volume><issue>10</issue><fpage>1883</fpage><lpage>1897</lpage><history>
<date date-type="received"><day>27</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>17</day><month>4</month><year>2025</year></date>
<date date-type="rev-recd"><day>16</day><month>4</month><year>2025</year></date>
<date date-type="online"><day>30</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" content-type="AuthorChoicev2" start_date="2025-04-30"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-04-30">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><abstract><p>Chaperones may retard
the aggregation of other proteins and increase
their solubility. An important goal is a thermodynamic understanding
of such an action. Here, the chaperone DNAJB6b (JB6) is found to suppress
amyloid formation of the protein &#x003b1;-synuclein (&#x003b1;-syn) leading
to a reduced rate of fibril formation and an increase in apparent
solubility of &#x003b1;-syn. These findings were reached at mildly acidic
pH and with light seeding under conditions where the effect on secondary
nucleation is visible. Cryo-transmission electron microscopy (cryo-TEM)
imaging reveals that coaggregates of &#x003b1;-syn and JB6 are formed
with significantly altered ultrastructure compared to both pure protein
fibrils and pure chaperone aggregates. This is further supported by
the formation of ThT-negative aggregates and by the depletion of JB6
from solution in the presence of &#x003b1;-syn. The identification of
such coaggregates provides a plausible thermodynamic explanation for
an increase in &#x003b1;-syn solubility in the presence of JB6; the
reduced chemical potential of the chaperone upon formation of coaggregates
can compensate for an increased chemical potential of &#x003b1;-syn,
and the system as a whole can lower its free energy to sustain an
increased free &#x003b1;-syn concentration.</p></abstract><abstract abstract-type="graphical"><graphic xlink:href="cn4c00883_0013.jpg" position="float"/></abstract><abstract abstract-type="toc-graphic"><graphic xlink:href="cn4c00883_0011.jpg" id="tgr1" specific-use="not-for-print" position="float"/></abstract><kwd-group><kwd>self-assembly</kwd><kwd>chaperone action</kwd><kwd>solubility
enhancement</kwd><kwd>coaggregation</kwd><kwd>aggregation rate</kwd><kwd>aggregation equilibrium</kwd></kwd-group><funding-group><award-group id="fnd-1"><funding-source>
<institution-wrap><institution>European Research Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000781</institution-id></institution-wrap>
</funding-source><award-id>ERC 101097824</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source>
<institution-wrap><institution>Knut och Alice Wallenbergs Stiftelse</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004063</institution-id></institution-wrap>
</funding-source><award-id>KAW 2022-0059</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source>
<institution-wrap><institution>Vetenskapsr?det</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100004359</institution-id></institution-wrap>
</funding-source><award-id>VR 2015-00143</award-id></award-group></funding-group><funding-group><award-group id="fnd-4"><funding-source>
<institution-wrap><institution>NanoLund, Lunds Universitet</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100019166</institution-id></institution-wrap>
</funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>cn4c00883</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>cn4c00883</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>370ca87ae3aa5c10891ac41aca51da8431cdb08a2a373299a23faa199320f18c</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Protein misfolding and
aggregation into amyloid fibrils are linked
to several neurodegenerative disorders, such as Parkinson&#x02019;s,
Alzheimer&#x02019;s, and Huntington&#x02019;s disease.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>&#x02212;<xref rid="ref2" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref3" ref-type="bibr"/>
</named-content> An important group of proteins, named molecular chaperones, are
components of the protein quality control system. They may promote
folding, prevent misfolding or aggregation of other proteins in vivo
and in vitro, and promote degradation through interactions with ubiquitin
ligase complexes and proteases as well as through autophagy.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#x02212;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content> Effects are observed both in terms of rate and equilibrium, with
the inhibition of aggregation processes starting from excess free
monomers and dissociation of excess aggregates.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>&#x02212;<xref rid="ref10" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref11" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref12" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref13" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref14" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref18" ref-type="bibr"/>
</named-content> Given the prominent role of chaperones in modulating amyloid formation,
comprehensive studies of their impact and the molecular basis of
their action may guide the therapeutic interventions of neurodegenerative
diseases.</p><p>&#x003b1;-syn is found in nearly all neuronal compartments
in the
human body, and it is enriched in the presynaptic terminals.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref20" ref-type="bibr"/>
</named-content> It consists of 140 residues with a remarkably segregated primary
structure that can be divided into three regions: the N-terminal amphipathic
region, a central hydrophobic nonamyloid-&#x003b2; component (NAC) region,
and the acidic C-terminal tail. It can also be divided into: the N-terminal
tail, the fibril core, and the C-terminal tail based on the fold of
the monomers in amyloid fibrils (see, for example, <ext-link xlink:href="2N0A" ext-link-type="PDB">2N0A</ext-link>.pdb) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>A).<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>&#x02212;<xref rid="ref21" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref22" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref23" ref-type="bibr"/>
</named-content> In its monomeric form in solution,
&#x003b1;-syn, is intrinsically disordered. However, when bound to lipid
membranes, its first up to 95 residues may take on an &#x003b1;-helical
conformation.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>&#x02212;<xref rid="ref21" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref22" ref-type="bibr"/>,<xref rid="ref24" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig1" fig-type="figure"><label>1</label><caption><p>Structures and sequences
of &#x003b1;-syn and JB6. (A) Distribution
of acidic (red), basic (blue), hydrophobic (yellow), and polar and
noncharged (white) residues within the &#x003b1;-syn sequence. At the
top of the representation, the 140-residue-long sequence is divided
into the N-terminal amphipathic region (1&#x02013;60), central hydrophobic
NAC region (61&#x02013;95), and C-terminal tail (96&#x02013;140), based
on its primary structure. Below, the representation of the sequence
is divided into three regions: N-terminal tail, fibril core, and C-terminal
tail based on the folding of the monomers into amyloid fibrils. Comparison
between available structural models reveals variation in how many
residues belong to the fibril core, ranging from residue 2 to 104
(dashed lines in panel (A)). The C-terminal tail is unstructured in
all available structural models. (B) Structure (pdb: <ext-link xlink:href="2N0A" ext-link-type="PDB">2N0A</ext-link>
<xref rid="ref58" ref-type="bibr"/>) of &#x003b1;-syn proto-filaments, showing 10 planes of monomers,
colored according to the N-terminal tail (blue), the fibril core (gray),
and the C-terminal tail (red) shown as CPK model. (C) Ribbon model
of the JB6 monomer predicted by AlphaFold 2<xref rid="ref52" ref-type="bibr"/> colored as J-domain (orange), low-complexity region (green), and
CTD (blue). (D) Sequence overview of DNAJB6b.</p></caption><graphic xlink:href="cn4c00883_0001" id="gr1" position="float"/></fig><p>&#x003b1;-syn has been found to play diverse roles in neuronal physiology
and synaptic plasticity, facilitating vesicle trafficking and secretion
in cells, such as exo- and endocytosis of synaptic vesicles.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>,<xref rid="ref25" ref-type="bibr"/>,<xref rid="ref26" ref-type="bibr"/>
</named-content> &#x003b1;-syn can, however, also
misfold and form toxic oligomeric species and amyloid fibrils, which
can accumulate into Lewy bodies associated with synucleinopathies,
such as Parkinson&#x02019;s disease.<named-content content-type="bibref-group">
<xref rid="ref20" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>,<xref rid="ref28" ref-type="bibr"/>
</named-content> The fibril formation of &#x003b1;-syn occurs via primary
nucleation, secondary nucleation, and elongation under quiescent conditions.
To our knowledge, primary nucleation of &#x003b1;-syn in bulk has never
been confirmed at physiologically relevant conditions, while heterogeneous
nucleation at surfaces is well established.<named-content content-type="bibref-group">
<xref rid="ref29" ref-type="bibr"/>&#x02212;<xref rid="ref30" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref31" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref32" ref-type="bibr"/>
</named-content> The rate of fibril formation
has previously been found to be significantly higher at mildly acidic
pH compared to neutral pH, with the rate of secondary nucleation being
4 orders of magnitude higher at pH 5.2 than 7.4.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>&#x02212;<xref rid="ref34" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref35" ref-type="bibr"/>
</named-content> The mildly
acidic conditions within late endosomes and secretory granules involved
in endo- and exocytosis,<named-content content-type="bibref-group">
<xref rid="ref36" ref-type="bibr"/>&#x02212;<xref rid="ref37" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref38" ref-type="bibr"/>
</named-content> motivates studies in this pH
range.</p><p>DNAJB6b (JB6) belongs to class B of the family of DNAJ
molecular
chaperones (previously called Hsp40) with over 40 members that may
regulate and stabilize the interactions between Hsp70s and their substrates
by stimulating the ATPase activity of the Hsp70s.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref39" ref-type="bibr"/>&#x02212;<xref rid="ref40" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref41" ref-type="bibr"/>
</named-content> JB6 exists within various organs of the human body,
including the neuronal cells in the brain.<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref43" ref-type="bibr"/>
</named-content> It is present within both the cytosol and the nucleus. JB6 has been
shown to suppress Parkinson&#x02019;s pathology and cell death in mouse
and cell models.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>,<xref rid="ref45" ref-type="bibr"/>
</named-content> It is present within the center of Lewy bodies and has been found
to be downregulated in Parkinson&#x02019;s disease patients.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>,<xref rid="ref46" ref-type="bibr"/>
</named-content> A mutated form of JB6 (T193A)
has also been found to increase the risk of Parkinson&#x02019;s disease
in carriers of a mutation in the &#x003b2;-glucocerebrosidase gene.<xref rid="ref47" ref-type="bibr"/> In vitro, JB6 suppresses the fibril formation
of several amyloidogenic proteins such as polyglutamine peptide,<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> amyloid &#x003b2; peptide (A&#x003b2;),<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/>
</named-content> and TDP43.<xref rid="ref49" ref-type="bibr"/>
</p><p>JB6 consists of an &#x003b1;-helical N-terminal domain
(residues
1&#x02013;71, the J-domain), linked to the &#x003b2;-sheet-rich C-terminal
domain (residues 185&#x02013;241, CTD) through a long and flexible
linker (residues 72&#x02013;184).<named-content content-type="bibref-group">
<xref rid="ref13" ref-type="bibr"/>,<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref50" ref-type="bibr"/>
</named-content> The domain structures are reported based on NMR spectroscopic
analysis for a variant with a shortened linker.<xref rid="ref51" ref-type="bibr"/> In an AlphaFold 2 model<xref rid="ref52" ref-type="bibr"/> of
monomeric JB6 shown in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>C, the domains are well predicted, but the flexible linker
is not. The linker sequence is of low complexity, abundant in phenylalanine
(F) and glycine (G) residues, and a region rich in serine (S) and
threonine (T) residues is located within the linker and the CTD (residues
155&#x02013;195).<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref53" ref-type="bibr"/>
</named-content>
</p><p>JB6 self-assembles into
large polydisperse oligomers at concentrations
above its critical micelle concentration (120 nM).<xref rid="ref50" ref-type="bibr"/> A recent study indicates that the active form responsible
for the retardation of the aggregation of A&#x003b2;42 is the small
subunit, rather than the larger oligomeric species.<xref rid="ref54" ref-type="bibr"/> The influence of various molecular chaperones on the aggregation
rates and mechanisms of amyloid fibril formation has been thoroughly
investigated. Molecular chaperones have been found to interact with
the monomers, oligomers, or fibrils and can impact any of the microscopic
processes of amyloid fibril formation in a system-dependent manner.<named-content content-type="bibref-group">
<xref rid="ref48" ref-type="bibr"/>,<xref rid="ref55" ref-type="bibr"/>&#x02212;<xref rid="ref56" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref57" ref-type="bibr"/>
</named-content> While intact JB6 inhibits both nucleation steps of
A&#x003b2;, the isolated CTD inhibits only secondary nucleation in A&#x003b2;
fibril formation.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content>
</p><p>In addition, molecular
chaperones can affect the relative stability
of the monomers and fibrillar forms, thus affecting the solubility
of the amyloidogenic proteins. For example, JB6 retards the aggregation
of A&#x003b2; and affects the end state, resulting in higher A&#x003b2;
solubility in the presence of the chaperone.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref15" ref-type="bibr"/>
</named-content>
</p><p>Here we have studied the effect of
the chaperone JB6 on the rate
of aggregation, as well as the solubility of the amyloidogenic protein
&#x003b1;-syn in vitro. The study was performed at mildly acidic pH
under light seeding conditions using fluorescence and NMR spectroscopy,
chromatography, and electrophoresis, whereby the effects of JB6 on
secondary nucleation and solubility can be studied. We also used cryo-transmission
electron microscopy (cryo-TEM) to compare the characteristics of the
&#x003b1;-syn aggregates formed in the presence and absence of JB6,
in addition to quantification of the solution composition. This enables
the discussion of a proposed thermodynamic explanation of the observed
increase in solubility in the presence of JB6.<xref rid="ref9" ref-type="bibr"/>
</p></sec><sec id="sec2"><label>2</label><title>Experimental Section</title><sec id="sec2.1"><label>2.1</label><title>Expression of &#x003b1;-syn</title><p>The gene
coding for wild-type human &#x003b1;-syn with <named-content content-type="genus-species">Escherichia
coli</named-content> (<named-content content-type="genus-species">E. coli</named-content>)-optimized
codons was cloned into a Pet3a-plasmid (purchased from GenScript,
Piscataway, New Jersey) with an ATG start codon (corresponding to
Met1) (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S1</ext-link>). The protein was
expressed in <named-content content-type="genus-species">E. coli</named-content> BL21 DE3_pLysS*
in LB medium, or autoinduction medium<xref rid="ref59" ref-type="bibr"/> for unlabeled protein, and in M9 minimal medium with <sup>15</sup>NHCl<sub>4</sub> for <sup>15</sup>N-labeled samples, all containing
30 &#x003bc;g/mL chloramphenicol and 50 &#x003bc;g/mL ampicillin at 37
&#x000b0;C in baffled flasks with 125 rpm shaking. Cells were harvested
by centrifugation at 6000<italic toggle="yes">g</italic> for 12 min at 4 &#x000b0;C
(JA 8.100 rotor, Avanti J-26 XP centrifuge, Beckman Coulter). The
cells obtained from a total of 4 L of culture were combined and mixed
with 25 mL of water and stored at &#x02212;20 &#x000b0;C until further
purification. Samples of 1 mL were taken from the culture right before
harvesting to test whether the expression was successful (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S2</ext-link>). The 1 mL samples were centrifuged
at &#x0223c;20,000<italic toggle="yes">g</italic>, the supernatant was disposed,
and the cell pellets were frozen at &#x02212;20 &#x000b0;C. The cell pellet
was thawed and fully resuspended in 100 &#x003bc;L sterile H<sub>2</sub>O, boiled for 1 min, and centrifuged for 10 min at &#x0223c;20,000<italic toggle="yes">g</italic>. The supernatant and the pellet (8 &#x003bc;L) were run
on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
using 4&#x02013;20% precast Tris/Tricine gels (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>).</p></sec><sec id="sec2.2"><label>2.2</label><title>Purification of &#x003b1;-syn</title><p>The frozen
cell pellet from a 4 L culture was resuspended in cold &#x0223c;100
mL of buffer A (10 mM Tris/HCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), pH 7.5) and placed on ice (volume of buffer versus cell pellet
was ca. 5:1). The sample was sonicated using pulsed sonication (1
s on, 1 s off) until the sample was homogeneous. This was done stepwise,
and the sample was placed on ice the whole time in order not to heat
the sample. After sonication, the sample was centrifuged for 10 min
at 15,000<italic toggle="yes">g</italic> at 4 &#x000b0;C (JA 25.50 rotor, Avanti J-26
XP centrifuge, Beckman Coulter). Supernatant was collected and poured
into an equal amount of boiling buffer A. The sample was stirred continuously,
and the temperature was monitored carefully. When the temperature
had reached 85 &#x000b0;C, the sample was placed back on ice, and stirring
was continued until the sample had cooled down. If a light-colored
pellet remained after the first sonication and centrifugation, the
procedure was repeated to maximize the yield. The cooled sample was
centrifuged for 10 min at 15,000<italic toggle="yes">g</italic> and 4 &#x000b0;C (JA25.50
rotor, Avanti J-26 XP centrifuge, Beckman Coulter) in order to remove
the majority of the precipitated <named-content content-type="genus-species">E. coli</named-content> proteins. The supernatant was collected and saved for further purification.</p><p>The first ion-exchange chromatography step was performed using
a 3.5 cm diameter column with 100 g diethylaminoethyl (DEAE) cellulose
conditioned in buffer A. All buffers were degassed and filtered using
a hydrophilic polypropylene membrane filter, 0.2 &#x003bc;m (Pall Corporation),
kept cold, and the purification was performed in a cold room. Using
a pump, the sample was slowly loaded onto the column (&#x0223c;2 mL/min),
which was then washed with a minimum of 100 mL of buffer A at 1 mL/min
and eluted with 1.4 L of linear 0&#x02013;0.5 M NaCl gradient in buffer
A at 1 mL/min. The eluate was collected into fractions and analyzed
with agarose gel electrophoresis or SDS-PAGE (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S3</ext-link> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>). The
fractions containing mainly &#x003b1;-syn and minimal impurities were
combined and diluted in an equal amount of buffer A and further purified
by a second ion-exchange chromatography step.</p><p>The second ion-exchange
chromatography step was performed in the
same way as described above, except for this time using 60 g of DEAE
sephacel resin and a column of 2.3 cm diameter (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S3</ext-link>). The fractions were analyzed by measuring the
absorbance at 280 nm. To determine the purity and the presence of
&#x003b1;-syn, the fractions showing absorbance at 280 nm were analyzed
by SDS-PAGE before the corresponding fractions containing &#x003b1;-syn
without any detectable impurities were collected, combined, and stored
at &#x02212;20 &#x000b0;C in 1 mL aliquots. The concentration of the pooled
sample was between 70 and 210 &#x003bc;M for all batches based on absorbance
at 280 nm, using an extinction coefficient: &#x003b5;<sub>280nm</sub> = 5800 M<sup>&#x02013;1</sup> cm<sup>&#x02013;1</sup>. The purity
of the sample was confirmed by the absence of any additional bands
on SDS-PAGE (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S3</ext-link> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>). The identity and quality were confirmed
with mass spectrometry and by performing aggregation kinetics for
each batch.</p></sec><sec id="sec2.3"><label>2.3</label><title>Expression and Purification
of DNAJB6</title><p>A tag-free DNAJB6b (the gene sequence is presented
in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S4</ext-link>) was expressed in autoinduction
medium<xref rid="ref59" ref-type="bibr"/> and purified using sonication
at pH 6.0 and
8.0, removal of contaminants on ion-exchange resins, followed by ammonium
sulfate precipitation and two size exclusion steps with and without
1.6 M GuHCl as described.<xref rid="ref60" ref-type="bibr"/> An SDS-PAGE
analysis of the different JB6 batches used in this study is shown
in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S5 and Figure S4</ext-link>.</p></sec><sec id="sec2.4"><label>2.4</label><title>Monomer Preparation Using Size Exclusion Chromatography</title><p>The 1 mL aliquots of &#x003b1;-syn were lyophilized and dissolved
in 1.1 mL of 6 M guanidinium hydrochloride and thoroughly mixed using
a vortex mixer. The number of tubes dissolved in a total volume of
1.1 mL depends on the required sample concentration. The sample was
left at room temperature (RT) for at least an hour to ensure that
it completely dissolved. Thereafter, the sample was loaded onto a
Superdex 75 Increase 10/300 GL (GE Healthcare) size exclusion column
(SEC) using a fast protein liquid chromatography (FPLC) system (Bio-RAD
BIOLOgic Fuo Flow, Hercules, CA), which had been equilibrated with
the experimental buffer. Buffers were freshly prepared, filtered,
and degassed prior to each experiment. The sample was eluted at a
flow rate of 0.7 mL/min, and the absorbance at 280 nm was recorded
to follow the elution of the monomers. The fractions corresponding
to the center of the monomer peak (ca. 1&#x02013;1.5 mL) (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S6 and Figure S5A</ext-link>) were collected into
low-binding tubes (Genuine Axygen Quality or Eppendorf Protein LoBind
tubes) and kept on ice until the start of the experiment. The concentration
of the sample was determined from the absorbance at 280 nm using &#x003b5;<sub>280nm</sub> = 5800 M<sup>&#x02013;1</sup> cm<sup>&#x02013;1</sup>.
Between monomer isolation rounds, the column was cleaned with 10 mL
of 50% formic acid, 10 mL of 0.5 M NaOH, and 10 mL of 1 M Tris, with
one column volume of water between each solution. The cleaning steps
are critical for maintaining the purity of the samples. The column
is stored in 20% EtOH.</p></sec><sec id="sec2.5"><label>2.5</label><title>Aggregation Kinetics</title><p>Aggregation
kinetics of &#x003b1;-syn in the presence and absence of JB6 were monitored
by measuring thioflavin T (ThT) fluorescence using excitation and
emission wavelengths of 440 and 480 nm, respectively. ThT binds to
amyloid fibrils, constraining the rotation of a carbon&#x02013;carbon
bond between two rings, leading to an increase in fluorescence quantum
yield. 100 &#x003bc;L samples were incubated in a 96-well half-area
low-binding polyethylene glycol (PEG)-coated polystyrene plate (3881,
Corning) with a transparent bottom and sealed with a SealPlate film
(Excel Scientific). Samples were incubated at 37 &#x000b0;C without shaking.
The final concentration of &#x003b1;-syn was 20 &#x003bc;M, and the final
concentration of JB6 ranged from 7.8 to 125 nM (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). Experiments were performed in either 10
mM 2-(<italic toggle="yes">N</italic>-morpholino)&#x000ad;ethansulfonic acid (MES), 1.4
mM sodium phosphate (NaP), 0.02% NaN<sub>3</sub> pH 5.5 or 10 mM acetate,
0.7 mM NaP, 0.02% NaN<sub>3</sub>, pH 4.5. Experiments were performed
using 1% of seeds (final concentration 200 nM). The seeds are fibrils
formed by incubating 20 &#x003bc;M freshly prepared &#x003b1;-syn in a
low-binding tube with 700 rpm stirring using a magnetic stir bar at
37 &#x000b0;C for 2 days (until the final plateau is reached), aliquoted,
and frozen at &#x02212;20 &#x000b0;C. The seeds were made in 10 mM MES/NaOH,
pH 5.5, 0.02% NaN<sub>3</sub> or 10 mM acetate, pH 4.5, 0.02% NaN<sub>3</sub>, depending on the experimental conditions. The free monomer
is &#x0003c;0.2 &#x003bc;M in the 20 &#x003bc;M seed stock at pH 5.5, and the
free monomer is thus not separated from the seeds before adding them
at low concentration (200 nM seed + &#x0003c;2 nM monomer) to the freshly
purified 20 &#x003bc;M monomer. Before each aggregation kinetic experiment,
the seeds were thawed and placed in a sonication bath for 1 min prior
to incubation at RT for a minimum of 1 h.</p><fig position="float" id="fig2" fig-type="figure"><label>2</label><caption><p>Suppression of &#x003b1;-syn
fibril formation by JB6 at a mildly
acidic pH at 37 &#x000b0;C. (A) Aggregation was followed by monitoring
ThT fluorescence. The aggregation kinetics of 20 &#x003bc;M &#x003b1;-syn
at pH 5.5 was studied in the presence of 125 nM (0.6%), 62.5 nM (0.3%),
31.3 nM (0.15%), 15.6 nM (0.08%), and 7.8 nM (0.04%) JB6. Three replicates
are shown for each condition. Data for up to 188 h are shown in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S8</ext-link>. (B) Relative half-times (<italic toggle="yes">t</italic>
<sub>1/2</sub>) &#x003b1;-syn in the presence of 62.5 nM
(0.3%), 31.3 nM (0.15%), 15.6 nM (0.08%), and 7.8 nM (0.04%) JB6.
The half-times positively correlate with JB6 concentration with an <italic toggle="yes">R</italic>
<sup>2</sup> of 0.97.</p></caption><graphic xlink:href="cn4c00883_0002" id="gr2" position="float"/></fig></sec><sec id="sec2.6"><label>2.6</label><title>Solubility Measurements</title><sec id="sec2.6.1"><label>2.6.1</label><title>Solubility
Measured by SDS-PAGE</title><p>The kinetic experiments from which samples
were collected for solubility
determination were performed according to the procedure in <xref rid="sec2.5" ref-type="sec">Section <xref rid="sec2.5" ref-type="sec"/>
</xref> in 10 mM MES/NaOH,
1.4 mM NaP, 0.02% NaN<sub>3</sub> pH 5.5. Samples were withdrawn from
the plate by pipetting up and down a few times and scraping the bottom
of the well carefully using the pipet tip. Separation of free monomers
and fibrils was done by centrifugation at 31,510<italic toggle="yes">g</italic> for 90 min at RT in 1.5 mL low-binding tubes. The supernatant was
analyzed with SDS-PAGE (<xref rid="sec2.7" ref-type="sec">Section <xref rid="sec2.7" ref-type="sec"/>
</xref>). From the SDS-PAGE, the intensity of the bands was
analyzed by using the software ImageJ.</p></sec><sec id="sec2.6.2"><label>2.6.2</label><title>Solubility
Measured by HPLC-MS</title><p>The kinetic experiment from which the
sample was extracted for solubility
determination was performed according to the procedure in <xref rid="sec2.5" ref-type="sec">Section <xref rid="sec2.5" ref-type="sec"/>
</xref> in 10 mM MES,
1.4 mM NaP, and 0.02% NaN<sub>3</sub>, pH 5.5. Seeds used were made
in 10 mM MES, 0.02% NaN<sub>3</sub>, and pH 5.5. The &#x003b1;-syn concentrations
were 20 &#x003bc;M monomer and 200 nM seeds (1%). The JB6 concentrations
ranged from 7.8 to 125 nM. After 45, 140, and 188 h, one of the three
replicates at each JB6 concentration was transferred into low-binding
tubes and centrifuged at 31,510<italic toggle="yes">g</italic> for a minimum of
1 h. The supernatant was used for quantification by HPLC-MS (Shimadzu
Corporation), and the protein concentration was quantified by measuring
absorbance during elution of a reversed-phase column (BIOshell A160
Peptide CN, 5 cm &#x000d7; 2.1 mm, 2.7 &#x003bc;M). 10 &#x003bc;L of supernatant
was injected onto the column and eluted using a gradient from 5 to
95% acetonitrile in water, with 0.1% trifluoroacetic acid (TFA) at
a flow rate of 0.5 mL/min. The absorbance was measured at 205 and
280 nM. Area integration was conducted with the instrument software.
A standard curve, recorded for &#x003b1;-syn monomer in the range of
20&#x02013;0.041 &#x003bc;M, was used. The monomer concentration of the
injected supernatant was estimated via the absorbance at either 280
nm (for the higher concentrations) or 205 nm (for the lower concentrations).
Additionally, the same samples (supernatants) were analyzed by SDS-PAGE
(see <xref rid="sec2.7" ref-type="sec">Section <xref rid="sec2.7" ref-type="sec"/>
</xref>).</p></sec><sec id="sec2.6.3"><label>2.6.3</label><title>Solubility Measured by NMR</title><p>The
samples for the NMR experiments were prepared in 10 mM MES, 1.4 mM
NaP, 0.02% NaN<sub>3</sub>, pH 5.5 with 20 &#x003bc;M <sup>15</sup>N-labeled
&#x003b1;-syn, 1% seeds, 10 &#x003bc;M free <sup>15</sup>N-labeled tryptophan,
sodium trimethylsilylpropanesulfonate (DSS), and 10% D<sub>2</sub>O. 550 &#x003bc;L samples were also prepared with or without 250 nM
nonlabeled DNAJB6b. One-dimensional (1D) <sup>1</sup>H and two-dimensional
(2D) <sup>1</sup>H&#x02013;<sup>15</sup>N heteronuclear single quantum
coherence (HSQC) NMR spectra were recorded at 37 &#x000b0;C using a Bruker
Avance Neo 800 MHz spectrometer with TCI 5 mm CryoProbe (Bruker Biospin,
Rheinstetten, Germany). The 1D <sup>1</sup>H spectra were recorded
using water suppression at 4.7 ppm with excitation sculpting<xref rid="ref61" ref-type="bibr"/> combined with a perfect echo<xref rid="ref62" ref-type="bibr"/> using the standard Bruker pulse-program zgesgppe. The spectral
width was 15.6 ppm with 32,768 points, 1.3 s acquisition time, 128
scans, and an interscan delay of 1.5 s. The total experimental time
was 6 min 30 s. The 2D <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC spectra
were recorded using sensitivity-enhanced gradient coherence selection<xref rid="ref63" ref-type="bibr"/> using the standard Bruker pulse-program. The
spectral width was 14.2 ppm with 2048 points, 90 ms acquisition time,
and transmitter frequency offset at 4.7 ppm in the direct dimension
(<sup>1</sup>H). The spectral width in the indirect dimension was
34 ppm, 128 points, and the transmitter frequency offset at 118 ppm.
The interscan delay was 1 s, resulting in a total experimental time
of 20 min. Data was processed with TopSpin 4.3.0, and an exponential
window function with line broadening of 2 Hz was used for the 1D data.
The integration of the peaks covered the envelope of the amide region
7.8&#x02013;9.0 ppm. For processing of the 2D data prior to Fourier
transformation, linear prediction and zero filling in the indirect
dimension were applied to yield the final data set of 2048 &#x000d7;
512 points.</p></sec></sec><sec id="sec2.7"><label>2.7</label><title>Sodium Dodecyl Sulfate-Polyacrylamide
Gel
Electrophoresis (SDS-PAGE) Analysis</title><p>Samples were analyzed
by SDS-PAGE using Novex 10&#x02013;20% Tris/Tricine gels (Invitrogen
by Thermo Fisher Scientific). Samples were mixed 1:1 with loading
buffer, and 10 &#x003bc;L was carefully loaded onto each well. The standard
used was a PageRuler prestained protein ladder (Thermo Fisher Scientific,
Waltham, MA). Gels were stained using 15 mL InstantBlue Coomassie
Protein Stain (ISB1L, Abcam Ltd.).</p><p>In addition to the supernatant
samples, monomeric &#x003b1;-syn of known concentration was loaded onto
the gel (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S9</ext-link>) and used as a concentration reference for
the signal intensity of the supernatants. The electrophoresis was
run at 70 V for 15 min and at 120 V for 60 min. The gel was washed
with Milli-Q water and incubated in the stain with slow rocking at
RT overnight. The following day, the staining was replaced with water
and left on the shaker for a minimum of 1 h before imaging.</p><fig position="float" id="fig3" fig-type="figure"><label>3</label><caption><p>Quantification
of &#x003b1;-syn apparent solubility at different
concentrations of JB6 at pH 5.5 and 37 &#x000b0;C. Color coding applies
to panels (A)&#x02013;(C). (A) Apparent solubility of &#x003b1;-syn in
the presence of different concentrations of JB6. The total concentration
of &#x003b1;-syn in all samples is 20 &#x003bc;M. Steady state appears
to be reached for all samples except for the one with 125 nM JB6 (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S7</ext-link> where a plateau is reached for all
samples except for those with 125 nM JB6). The &#x003b1;-syn concentration
in the supernatant was measured at three time points with two methods.
Filled circles represent monomer concentration measured with absorbance
using high-performance liquid chromatography-mass spectrometry (HPLC-MS).
&#x000d7; symbols represent SDS-PAGE analysis with the intensity of &#x003b1;-syn
in the supernatant normalized against the intensity of 20 &#x003bc;M
&#x003b1;-syn monomer. (B) SDS-PAGE of supernatant samples at 45 h and
standard samples of pure monomeric &#x003b1;-syn. Gels at 140 and 188
h are shown in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S9</ext-link>. (C) HPLC-MS trace
at 280 nm of the supernatant sample at 45 h (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S8</ext-link> for full trace). (D) Correlation between HPLC-MS
measured monomer concentration and normalized band intensity from
SDS-PAGE. Data points at each time point cover all six JB6 concentrations.</p></caption><graphic xlink:href="cn4c00883_0003" id="gr3" position="float"/></fig></sec><sec id="sec2.8"><label>2.8</label><title>Cryo-TEM</title><p>The samples
used for the
images presented in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref> were prepared at pH 4.5 in a 96-well half-area low-binding
PEG-coated polystyrene plate (3881, Corning) with a transparent bottom
and sealed with a SealPlate film (Excel Scientific) (according to <xref rid="sec2.5" ref-type="sec">Section <xref rid="sec2.5" ref-type="sec"/>
</xref>). Samples were
collected into low-binding Eppendorf tubes at the end of the corresponding
kinetic experiment by carefully pipetting up and down and scraping
the bottom of the well, using a pipet tip (this was done to ensure
that the aggregates that sediment and stick to the bottom of the wells
were collected). The samples used for the images presented in <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref> were also prepared
in a 96-well half-area low-binding PEG-coated polystyrene plate with
a transparent bottom, sealed with a film, and incubated for 2 days.
The samples were prepared at four different pH values: 4.0, 4.5, and
5.0, 10 mM acetate buffer, 0.02% NaN<sub>3</sub>, and pH 5.5 (10 mM
MES/NaOH, 0.02% NaN<sub>3</sub>). The samples were collected as described
above.</p><p>Specimens for cryo-TEM were prepared in an automatic
plunge freezer system (Leica EM GP). The climate chamber temperature
was kept at 21 &#x000b0;C, and relative humidity was &#x02265;90% to minimize
loss of solution during sample preparation. The specimens were prepared
by placing 4 &#x003bc;L of solution on glow-discharged lacey Formvar
carbon-coated copper grids (Ted Pella) and blotted with filter paper
before being plunged into liquid ethane at &#x02212;183 &#x000b0;C. This
leads to vitrified specimens, avoiding component segmentation and
rearrangement, and the formation of water crystals, thereby preserving
original microstructures.</p><p>The vitrified specimens were stored
under liquid nitrogen until
they were imaged. A Fischione Model 2550 cryo transfer tomography
holder was used to transfer the specimen into the electron microscope,
JEM 2200FS, equipped with an in-column energy filter (Omega filter),
which allows zero-loss imaging. The acceleration voltage was 200 kV
and zero-loss images were recorded digitally with a TVIPS F416 camera
using SerialEM under low dose conditions with a 10 eV energy selecting
slit in place.</p><p>The diameter of the fibrils was measured at multiple
different
locations along different aggregates in different images. This was
done by using the ruler tool in Adobe Photoshop.</p></sec><sec id="sec2.9"><label>2.9</label><title>Observation of ThT-Positive and ThT-Negative
Aggregates</title><p>At the end of the kinetic experiments (10 mM MES,
1.4 mM NaP, 0.02% NaN<sub>3</sub>, pH 5.5, 20 &#x003bc;M ThT), the samples
were collected and centrifuged for 30 min at 14,200<italic toggle="yes">g</italic> to separate aggregates from free monomers. The color of the pellets
obtained after the centrifugation step was compared and photographed.
For comparison, samples containing JB6 only at the highest concentration
(2 &#x003bc;M) were also inspected and documented in the same way.</p></sec><sec id="sec2.10"><label>2.10</label><title>pH Dependence of DNAJB6 Aggregate Stability</title><p>The pH dependence of JB6 aggregate stability was investigated by
recording the scattered light intensity at 90&#x000b0; while varying
the pH in a Labbot instrument (Probation Laboratories Sweden AB) using
laser light at 635 nm. The pH was measured continuously using an Orion
star A211 pH meter connected to an Orion ROSS Combination pH Micro
Electrode and the Labbot instrument. 1 mL of 2 &#x003bc;M JB6 in 10
mM acetate buffer at pH 4.0 was added to a Quartz SUPRASIL (HellmaAnalytics)
cuvette with a path length of 10 mm. A micro stir bar (8 mm &#x000d7;
1.5 mm, polytetrafluoroethylene (PTFE) coated) was added to the cuvette,
and the sample was continuously stirred at around 500 rpm at 25 &#x000b0;C.
The pH value and the light scattering intensity were measured every
60 s. 0.05 &#x003bc;L of the titrant, 1 M NaOH, was added to the sample
every 300 s. The detected light scattering is presented in arbitrary
units, in which 1 unit equals 1 ppm of the detector maximum output.</p></sec><sec id="sec2.11"><label>2.11</label><title>Adsorption of JB6 to Experimental Surfaces</title><p>The absorption of 250 nM JB6 (in 10 mM MES, 1.4 mM NaP, 0.02% NaN<sub>3</sub>, pH 5.5) to a low-binding 96-well half-area PEG-coated polystyrene
plate (3881, Corning) and NMR tubes made from borosilicate glass,
Type 1 Class B standard, recognized as N51A (Wilmad-LabGlass SP ScienceWare
5 mm O.D. Thin Walled Economy NMR Tubes). 250 nM JB6 was prepared
in LoBind Eppendorf Tubes. Samples were treated in an identical way
and transferred to NMR tubes and plates using Henke-Ject syringe (Henke
Sass Wold, Germany) attached to a 0.80 &#x000d7; 80 mm<sup>2</sup> Sterican
needle (B. Braun, Germany). 1.6 mL of sample was added into each NMR
tube, and 100 &#x003bc;L of sample was added into each well in the plate.
Samples were incubated at 37 &#x000b0;C for 1.5 h, 4 h, and 1 day. 100
&#x003bc;L of sample was taken from each replicate from the NMR tube,
by not touching the walls of the NMR tube while withdrawing the sample.
20 &#x003bc;L was taken from the middle of each well, without touching
the surfaces, and samples from three wells were combined for each
replicate to reach 60 &#x003bc;L. Samples were analyzed by HPLC-MS,
with recording of the absorbance at 205 nm (2&#x02013;3 measurements
per replicate) and by SDS-PAGE.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>JB6 Inhibits the Aggregation of &#x003b1;-syn
at Mildly Acidic pH</title><p>The aggregation kinetics of 20 &#x003bc;M
&#x003b1;-syn in the presence of JB6 was investigated at mildly acidic
pH (pH 5.5), where secondary nucleation of &#x003b1;-syn is prominent.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref35" ref-type="bibr"/>
</named-content> The concentration of JB6 ranged from 7.8 to 125 nM, corresponding
to 0.04&#x02013;0.6% of the &#x003b1;-syn molar concentration. The results
show that JB6 suppresses &#x003b1;-syn aggregation at very low stoichiometric
ratios of JB6 and &#x003b1;-syn, where inhibition was observed also
at the lowest JB6 concentration, 7.8 nM (0.04% of the total &#x003b1;-syn
concentration). JB6 was found to fully inhibit the amyloid fibril
formation at the highest concentration (&#x02265;125 nM, i.e., &#x02265;0.6%
of the total &#x003b1;-syn concentration) over the experimental time
frame (188 h) (see <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A). The half-times of &#x003b1;-syn in the presence of JB6 were
found to increase linearly with the JB6 concentration (see <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B).</p></sec><sec id="sec3.2"><label>3.2</label><title>Change in the Apparent Solubility of &#x003b1;-syn
as a Function of JB6 Concentration</title><p>The amount of &#x003b1;-syn
monomer in solution after aggregation was measured with three different
methods: SDS-PAGE, HPLC-MS, and NMR spectroscopy.</p><sec id="sec3.2.1"><label>3.2.1</label><title>The
Effect on Apparent Solubility Measured
by SDS-PAGE and HPLC-MS</title><p>For HPLC-MS (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A) and SDS-PAGE (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B) analysis, samples were collected at different
time points from the kinetic experiment (see <xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S6</ext-link>), after
45, 140, and 188 h, centrifuged, and an equal volume of each supernatant
was analyzed (see <xref rid="sec2.6" ref-type="sec">Section <xref rid="sec2.6" ref-type="sec"/>
</xref>).</p><p>After 188 h (the experimental time frame), the equilibrium
appears to have been reached for all samples, except for the ones
supplemented with the highest JB6 concentration, 125 nM (0.6%) JB6
(see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S7</ext-link>), in which the concentration
of monomer left in solution was still very high, 16 &#x003bc;M.</p><p>HPLC-MS allows for &#x003b1;-syn monomer quantification down to the
nanomolar range. An exemplary HPLC trace of &#x003b1;-syn is shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C, from which the
apparent solubility could be determined (the HPLC-MS traces up to
6 min, showing all detectable peaks on the chromatogram, are presented
in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S7</ext-link>).</p><p>The &#x003b1;-syn monomer
concentration left in solution, measured
by HPLC-MS, was found to increase with the JB6 concentration (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, represented with
filled circles). At equilibrium, the apparent solubility was found
to be higher for all samples with JB6 than for &#x003b1;-syn alone.
The concentration of &#x003b1;-syn left in solution was measured as
0.8 &#x003bc;M for the sample containing &#x003b1;-syn alone, and 1.4,
2.0, 3.8, and 7.7 &#x003bc;M for the samples containing 7.8, 15.6, 31.3,
and 62.5 nM JB6, respectively. The concentration of &#x003b1;-syn remaining
in solution at 62.5 nM JB6 is thus a factor of 10 higher than that
for &#x003b1;-syn alone.</p><p>The same samples as used for HPLC-MS
were also analyzed by SDS-PAGE,
where the signal intensities of the bands were compared and analyzed
using ImageJ (a gel of samples harvested after 45 h incubation is
shown in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B).
SDS-PAGE of samples harvested after 140 and 188 h are shown in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S8</ext-link>. The results were consistent with the
HPLC-MS analysis, showing that the concentration of &#x003b1;-syn in
solution at steady state is higher in the presence of JB6 at all concentrations
tested (7.8&#x02013;125 nM or 0.04&#x02013;0.6%) compared to &#x003b1;-syn
alone, indicating an increase in &#x003b1;-syn solubility in the presence
of JB6.</p><p>In <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, the
band intensities of the gel in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B are normalized against that of 20 &#x003bc;M &#x003b1;-syn
monomer (represented with &#x000d7; in the figure). The signal intensities
above 1.0 are possibly attributed to experimental errors including
minor variations in the volumes of the samples loaded onto the gel.</p><p>The monomer concentrations from the HPLC-MS correlate with the
normalized band intensities from the SDS-PAGE, with <italic toggle="yes">R</italic>
<sup>2</sup> above 0.89 for all three time points, 45, 140, and 188
h (see <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D).
This linearity remains between the first measurement at 45 h and the
last one at 188 h, as evident by the <italic toggle="yes">R</italic>
<sup>2</sup> values only dropping slightly from 0.96 to 0.95.</p><p>The ThT fluorescence
signal intensity was affected in the presence
of JB6. This can be seen in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A, where the signal intensity at the final plateau
decreases with increased concentration of the JB6. The decrease in
signal may in part be due to reduced fibril concentration and in part
to changes in surface character of the aggregates. A lower amount
of free &#x003b1;-syn monomer was found left in solution in the samples
having a higher ThT fluorescence intensity at the final plateau. The
ThT fluorescence signal intensity at the final plateau may thus at
least in part report on the amount of fibrils formed.</p></sec></sec><sec id="sec3.3"><label>3.3</label><title>The Effect of JB6 Measured Directly Using
Solution-State NMR Spectroscopy</title><p>Here, we monitored the effect
of JB6 on the aggregation rate of &#x003b1;-syn using solution-state
NMR spectroscopy. This was done as a complement to the kinetic analysis
presented in <xref rid="sec3.1" ref-type="sec">Section <xref rid="sec3.1" ref-type="sec"/>
</xref>, where the formation of fibrils is indirectly monitored using
the fluorescent dye ThT. The NMR signals obtained for samples consisting
of monomers in the presence of the fibrils originate from the free
monomer in solution, as the fibrils are NMR invisible (signals from
fibrils are broadened beyond visibility). The recorded NMR spectra,
thus, directly report on the concentration of free monomer in the
sample during aggregation.</p><p>Samples of 20 &#x003bc;M <sup>15</sup>N-labeled &#x003b1;-syn alone and in the presence of 250 nM nonlabeled
JB6 were prepared in 10 mM MES, 1.4 mM NaP, 0.02% NaN<sub>3</sub>,
pH 5.5, 1% seeds, 10 &#x003bc;M free <sup>15</sup>N-labeled tryptophan
(Trp) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S9</ext-link> shows no significant impact
of Trp on aggregation kinetics), DSS, 10% D<sub>2</sub>O. As shown
in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A, the measured monomer concentration was found to
decrease over time in a sigmoidal manner. The retardation of the aggregation
in the presence of 250 nM JB6 (1.25%) is clearly visible, with half-times
of 35 and 4.9 h with and without JB6, respectively. This is consistent
with the ThT kinetic data (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A) showing significant retardation of &#x003b1;-syn aggregation
in the presence of JB6. It should be noted that in the NMR spectroscopy
experiments, higher molar ratios of JB6 are needed in order to observe
the same retardation effect of JB6 on &#x003b1;-syn aggregation as in
experiments performed in low-binding plates (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S8 and Figure S10</ext-link>). This can be explained by differences
in the experimental setup, such as differences in the container surface
properties, in the surface-to-volume ratios, and agitation,<xref rid="ref64" ref-type="bibr"/> which may affect the behavior of &#x003b1;-syn
and JB6. We find that JB6 adsorbs to the glass surface of the NMR
tubes but not to the low-binding plates used for the ThT kinetic experiments
(see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S9 and Figure S11</ext-link>).</p><fig position="float" id="fig4" fig-type="figure"><label>4</label><caption><p>NMR data for
&#x003b1;-syn with and without 250 nM JB6 at pH 5.5,
37 &#x000b0;C. (A) &#x003b1;-syn monomer concentration, determined through
integration of the amide region in the 1D <sup>1</sup>H spectra. Magnified
are the mean and standard deviation (SD) of the final intensity measurements
at around 300 h. (B) Superposition of the first recorded <sup>1</sup>H&#x02013;<sup>15</sup>N HSQC spectrum of each sample in panel (A)
(&#x003b1;-syn with 250 nM JB6 in red and without JB6 in blue). F1 on
the <italic toggle="yes">y</italic>-axis represents the chemical shift of <sup>15</sup>N signals and F2 on the <italic toggle="yes">x</italic>-axis of the <sup>1</sup>H signals. The figure was produced with TopSpin 4.3.0.</p></caption><graphic xlink:href="cn4c00883_0004" id="gr4" position="float"/></fig><p>Furthermore, an increase in the apparent solubility
of &#x003b1;-syn
in the presence of JB6 was observed after about 300 h. Averaging over
the integrated peak intensities shows 0.47 &#x000b1; 0.027 and 0.28 &#x000b1;
0.021 &#x003bc;M free &#x003b1;-syn monomers in solution with and without
JB6, respectively. The detected increase in apparent solubility is
consistent with the data shown in <xref rid="sec3.2" ref-type="sec">Section <xref rid="sec3.2" ref-type="sec"/>
</xref> (using low-binding surfaces), where we
in all cases detect an increase in the apparent solubility of &#x003b1;-syn
in the presence of JB6. The lower concentrations detected by NMR spectroscopy
are most likely related to the adsorption of JB6 onto the glass surface
of the NMR tubes, resulting in a lower amount of available JB6 in
solution (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S11</ext-link>).</p><p>
<sup>15</sup>N HSQC spectra of samples consisting of 20 &#x003bc;M
&#x003b1;-syn in the presence and absence of JB6 were superimposed,
showing no apparent effects of 250 nM or 2 &#x003bc;M JB6 on the detected
&#x003b1;-syn monomer signals (<xref rid="fig4" ref-type="fig">Figures <xref rid="fig4" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S12</ext-link>). The superimposed <sup>15</sup>N HSQC spectra at the respective <italic toggle="yes">t</italic>
<sub>1/2</sub> values also display no chemical shift changes in the monomer signal
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S12A</ext-link>). We would expect significant
binding in the case of 10% JB6 to be visible in the NMR spectrum (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S12B</ext-link>). Furthermore, we can not explain
the significant retardation with binding of JB6 to &#x003b1;-syn monomers
at low molar ratios. This further strengthens that JB6 binds mainly
to aggregated forms of &#x003b1;-syn, or forms coaggregates with the
&#x003b1;-syn.</p></sec><sec id="sec3.4"><label>3.4</label><title>Evidence of Coaggregation</title><p>In this
section, we present three lines of evidence for the formation of coaggregates
between &#x003b1;-syn and JB6. First, changes in the ultrastructure
were detected by cryo-TEM. Second, formation of ThT-negative aggregates
was observed in the presence of JB6. Finally, we measured the depletion
of JB6 from solution in the presence of &#x003b1;-syn, indicating the
association of JB6 and &#x003b1;-syn.</p><sec id="sec3.4.1"><label>3.4.1</label><title>The
Effect of JB6 on the Ultrastructure
of &#x003b1;-syn Fibrils Detected by Cryo-TEM</title><p>The structure
of &#x003b1;-syn fibrils in the presence of JB6 at different concentrations
was investigated by cryo-TEM at pH 4.5 and 5.5. The theoretical pI
value of JB6 is calculated to be 7.3 (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>).</p><table-wrap position="float" id="tbl1"><label>1</label><caption><title>Theoretical pI Value
of JB6<xref rid="t1fn1" ref-type="table-fn"/>
</title></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="char" char="&#x02013;"/><col align="char" char="."/></colgroup><thead><tr><th align="center">&#x000a0;</th><th align="center" char="&#x02013;">residues</th><th align="center" char=".">theoretical
pI value</th></tr></thead><tbody><tr><td align="left">whole sequence</td><td align="char" char="&#x02013;">1&#x02013;241</td><td align="char" char=".">7.3</td></tr><tr><td align="left">N-terminal domain</td><td align="char" char="&#x02013;">1&#x02013;71</td><td align="char" char=".">9.4</td></tr><tr><td align="left">linker</td><td align="char" char="&#x02013;">72&#x02013;184</td><td align="char" char=".">4.8</td></tr><tr><td align="left">C-terminal domain</td><td align="char" char="&#x02013;">185&#x02013;241</td><td align="char" char=".">10.0</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>The theoretical pI value of the
whole protein sequence (UniProt: O75190-2), as well as individual
parts, was calculated using the p<italic toggle="yes">K</italic>
<sub>a</sub> values
of model compounds<xref rid="ref65" ref-type="bibr"/> and the Henderson&#x02013;Hasselbalch
equation assuming ideal titrations. The titration of the N-terminus
was taken into account for JB6 and NTD. The titration of the C-terminus
was taken into account for JB6 and CTD.</p></fn></table-wrap-foot></table-wrap><p>The light scattering of JB6 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>) was measured at
90&#x000b0; as a function of pH by titrating the sample from low to high
pH with 1 M NaOH (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>A). Maximum scattering was observed at pH 5.5 for the JB6.
Cryo-TEM images of JB6 alone were obtained at four different pH values
(4.0, 4.5, 5.0, and 5.5). The cryo-TEM images did correlate well with
our scattering data, showing larger structures of JB6 at pH 5.0 and
5.5 compared with those at pH 4.0 and 4.5 (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>).</p><fig position="float" id="fig5" fig-type="figure"><label>5</label><caption><p>Light scattering and cryo-TEM images of JB6
alone as a function
of pH. (A) Right-angle light scattering of 2 &#x003bc;M JB6 in 10 mM
acetate buffer, 1.4 mM NaP, and 0.02% NaN<sub>3</sub> titrated with
1 M NaOH. Cryo-TEM images of 2 &#x003bc;M JB6 at (B) pH 4.0, (C) pH
4.5, (D) pH 5.0, and (E) pH 5.5.</p></caption><graphic xlink:href="cn4c00883_0005" id="gr5" position="float"/></fig><p>Furthermore, more clear cryo-TEM images of &#x003b1;-syn fibrils
alone were obtained at pH 4.5 compared with at pH 5.5. For comparison
of the ultrastructures of &#x003b1;-syn alone and in the presence of
JB6, cryo-TEM imaging was performed at both pH 4.5 (<xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S13&#x02013;S16</ext-link>) and pH 5.5
(see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S17</ext-link>).</p><fig position="float" id="fig6" fig-type="figure"><label>6</label><caption><p>Formation of coaggregates
of &#x003b1;-syn and JB6. Cryo-TEM and
kinetics analysis of &#x003b1;-syn in the presence of JB6 at pH 4.5
(10 mM acetate buffer, 1.4 mM NaP, and 0.02% NaN<sub>3</sub>). (A)
Comparison of aggregation rate and ThT fluorescence intensity between
20 &#x003bc;M &#x003b1;-syn alone (blue), and in the presence of 2 &#x003bc;M
(10%, red) and 0.13 &#x003bc;M (0.6%, purple) JB6, as well as 2 &#x003bc;M
JB6 alone (gray). (B) Average diameters of single &#x003b1;-syn fibrils
(blue) and coaggregates of &#x003b1;-syn and JB6 (10%, red) are 12.5
&#x000b1; 2.2 nm (<italic toggle="yes">n</italic> = 668) and 22.8 &#x000b1; 7.3 nm (<italic toggle="yes">n</italic> = 765), respectively. The data is visualized with a dot
plot, where each data point is represented with a dot and the average
and standard deviation are shown with black lines. (C&#x02013;F) Cryo-TEM
images showing different ultrastructure between the samples collected
at the end of the kinetic experiment: (C) 20 &#x003bc;M &#x003b1;-syn,
40k magnification. (D) 20 &#x003bc;M &#x003b1;-syn, 80k magnification.
(E) 20 &#x003bc;M &#x003b1;-syn + 2 &#x003bc;M JB6, 40k magnification. (F)
20 &#x003bc;M &#x003b1;-syn + 20 &#x003bc;M JB6, 80k magnification. The
scale bars correspond to 200 nm.</p></caption><graphic xlink:href="cn4c00883_0006" id="gr6" position="float"/></fig><p>JB6 suppresses the aggregation of &#x003b1;-syn at pH 4.5 (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>), leading to an
overall lower aggregation rate, consistent with the results presented
above for pH 5.5 (<xref rid="fig2" ref-type="fig">Figures <xref rid="fig2" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S17</ext-link>). Samples were collected
at the end of the experiment and analyzed with cryo-TEM. The sample
containing &#x003b1;-syn alone shows a large amount of bundled-up and
straight fibrils (see <xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig"/>
</xref>C,D, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S13, and S18</ext-link>), consistent
with previous observations for &#x003b1;-syn at mildly acidic pH.<xref rid="ref66" ref-type="bibr"/>
</p><p>The samples containing 2 &#x003bc;M JB6
alone at pH 4.5 show small
objects with a diameter of 6.2 &#x000b1; 1.1 nm (<italic toggle="yes">n</italic> =
60), potentially indicative of JB6 oligomers (see <xref rid="fig5" ref-type="fig">Figures <xref rid="fig5" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S14</ext-link>).</p><p>The images of &#x003b1;-syn in the presence of 2 &#x003bc;M
(10%) JB6
show aggregates that have remarkably different ultrastructures compared
to &#x003b1;-syn alone (see <xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig"/>
</xref>E,F and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S15</ext-link>). The aggregates
formed in the presence of JB6 are elongated fibrillar aggregates;
they appear less bundled and have varying thickness. The fibrils are
more irregular, with small knobs along the fibril structures. These
results strongly indicate that coaggregates of &#x003b1;-syn and JB6
are formed. The average diameter of single fibrils of &#x003b1;-syn
is smaller than for the coaggregates of &#x003b1;-syn and JB6, with
a diameter of 12.5 &#x000b1; 2.2 nm (<italic toggle="yes">n</italic> = 668) and 22.8
&#x000b1; 7.3 nm (<italic toggle="yes">n</italic> = 765), respectively (see <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>B). In the presence
of JB6 at the lower concentration, 125 nM (0.6%) (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S16</ext-link>), both types of structures are detected, corresponding
to the images containing &#x003b1;-syn alone (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>C,D) and in the presence of 2 &#x003bc;M (10%)
JB6 (coaggregates, <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>E,F).</p></sec><sec id="sec3.4.2"><label>3.4.2</label><title>Detection of ThT-Negative
Aggregates</title><p>The samples containing both &#x003b1;-syn and JB6
at high stoichiometric
ratios of chaperone to client (showing no increase in ThT fluorescence)
formed aggregates that were ThT-negative. This was investigated by
collecting the samples from the plate wells into Eppendorf tubes at
the end of a kinetic experiment, followed by centrifugation. After
2 days of incubation at 37 &#x000b0;C, the samples containing 20 &#x003bc;M
&#x003b1;-syn alone or JB6 at low stoichiometric ratios to &#x003b1;-syn
(20 &#x003bc;M &#x003b1;-syn and 16 nM JB6) showed an increase in the
ThT fluorescence intensity and had reached the final plateau (see <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>E). After centrifugation,
the corresponding samples consisted of supernatant and pellets of
a bright yellow color, indicative of ThT binding (see <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>A,B). On the other hand, the
samples that contained higher stoichiometric ratios of JB6 to &#x003b1;-syn
(20 &#x003bc;M &#x003b1;-syn and 2 &#x003bc;M JB6) showed no increase in
ThT fluorescence after 2 days of incubation at 37 &#x000b0;C. Despite
that, after centrifugation, the samples were separated into supernatant
and a pellet. The corresponding pellets were white and also smaller
than the yellow pellets in the other samples (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>C). This indicates that JB6 associates with
&#x003b1;-syn, forming coaggregates that do not enhance ThT fluorescence
to the same extent as that of the pure &#x003b1;-syn fibrils. This is
consistent with the cryo-TEM images showing that aggregates are present
in the samples of the higher stoichiometric ratios of JB6 to &#x003b1;-syn
that have no or a low increase in the ThT fluorescence intensity (<xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig"/>
</xref>E,F, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S15, and S17B</ext-link> (3 and 10% JB6)). For comparison,
samples containing JB6 alone were treated in the same manner and showed
no visible pellets (see <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>D), further supporting the conclusion of the formation of
ThT-negative coaggregates of &#x003b1;-syn and DNAJB6.</p><fig position="float" id="fig7" fig-type="figure"><label>7</label><caption><p>ThT-negative coaggregates.
Samples consisted of 20 &#x003bc;M &#x003b1;-syn
in the absence and presence of JB6 (2 &#x003bc;M and 16 nM), and 2 &#x003bc;M
JB6 alone in 10 mM MES, 1.4 mM NaPB, 0.02% NaN<sub>3</sub> at pH 5.5
with 20 &#x003bc;M ThT. Samples were collected after 2 days of incubation
(48 h) at 37 &#x000b0;C in low-binding plates without shaking, centrifuged,
and inspected, where the appearance of the pellets was compared. (A)
20 &#x003bc;M &#x003b1;-syn, showing a bright yellow pellet. (B) 20 &#x003bc;M
&#x003b1;-syn with 16 nM JB6, showing a bright yellow pellet. (C) 20
&#x003bc;M &#x003b1;-syn with 2 &#x003bc;M JB6, showing a white pellet,
(D) 2 &#x003bc;M JB6 alone, showing no pellet. (E) Kinetic traces of
the corresponding samples. The average of 3&#x02013;4 replicates is
shown in bold.</p></caption><graphic xlink:href="cn4c00883_0007" id="gr7" position="float"/></fig></sec><sec id="sec3.4.3"><label>3.4.3</label><title>Depletion
of JB6 from Solution</title><p>In parallel to the samples of &#x003b1;-syn
and JB6 at pH 4.5 being
analyzed by cryo-TEM imaging (see <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>), the same samples were centrifuged and
the supernatant was measured by HPLC-MS to compare the amount of &#x003b1;-syn
and JB6 in the supernatant. We detected depletion of JB6 from the
solution in the presence of &#x003b1;-syn based on the HPLC trace (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>A). For comparison,
samples of JB6 alone at pH 4.5 were centrifuged, and the supernatant
was analyzed by SDS-PAGE and compared to a sample that had not been
centrifuged (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Section S13</ext-link>). The result
shows that JB6 in the absence of &#x003b1;-syn stays in solution at
pH 4.5 (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">Figure S18</ext-link>). This is supported
by HPLC-MS analysis, showing that JB6 stays in solution in the absence
of &#x003b1;-syn (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>A). This, in conjunction with the results presented in <xref rid="sec3.4.1" ref-type="sec">Sections <xref rid="sec3.4.1" ref-type="sec"/>
</xref> and <xref rid="sec3.4.2" ref-type="sec">3.4.2</xref>, shows that larger sedimenting structures,
possibly coaggregates of JB6 and &#x003b1;-syn, are formed in the samples
consisting of &#x003b1;-syn and JB6, while no such structures are formed
in the samples consisting of JB6 alone, where JB6 stays in solution.</p><fig position="float" id="fig8" fig-type="figure"><label>8</label><caption><p>HPLC-MS
analysis of &#x003b1;-syn samples aggregated without or with
JB6 at different concentrations. The conditions are the same as those
in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A at pH
4.5. (A) HPLC-MS traces monitored with the absorbance at 205 nm after
injecting supernatants, with the color code below showing the initial
total sample compositions. The peaks at 4.5 and 5.2 min correspond
to &#x003b1;-syn and JB6, respectively. (B) &#x003b1;-syn concentration
in the supernatant as derived from the integration of the peak at
4.5 min.</p></caption><graphic xlink:href="cn4c00883_0008" id="gr8" position="float"/></fig><p>Furthermore, we detected an increase
in the apparent solubility
of &#x003b1;-syn in the presence of JB6 at pH 4.5 (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>B), consistent with the results
at pH 5.5 (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig"/>
</xref> and <xref rid="fig4" ref-type="fig"/>). The mean apparent solubility was
2.3, 0.88, and 0.13 &#x003bc;M at 2, 0.12, and 0 &#x003bc;M JB6, respectively.</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p>Extensive research has been
devoted to identifying and characterizing
substances that inhibit the formation of amyloid fibrils. These inhibitors
encompass a variety of compounds, including small molecules, antibodies,
and molecular chaperones.<named-content content-type="bibref-group">
<xref rid="ref55" ref-type="bibr"/>,<xref rid="ref67" ref-type="bibr"/>&#x02212;<xref rid="ref68" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref69" ref-type="bibr"/>
</named-content> In this study, we obtain strong indications that the molecular chaperone
JB6 affects the fibril formation of &#x003b1;-syn, in terms of both
kinetics, by retarding aggregation, and thermodynamics, by increasing
the apparent solubility of &#x003b1;-syn. This will be further discussed
in the following sections.</p><sec id="sec4.1"><label>4.1</label><title>Suppression of Amyloid
Formation</title><p>In this work, we show that the amyloid formation
of &#x003b1;-syn is
suppressed by JB6 in vitro in a concentration-dependent manner at
low stoichiometric ratios at pH 5.5, with molar ratios of JB6 to &#x003b1;-syn
down to 0.0004:1 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>).</p><p>In the kinetic experiments presented in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, the aggregation
was fully suppressed at the higher stoichiometric ratios within the
time frame tested. Similar results have previously been obtained for
polyglutamine peptide<xref rid="ref13" ref-type="bibr"/> and amyloid &#x003b2;
peptide.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/>
</named-content> Chaperones
have been found to affect the different microscopic steps of amyloid
fibril formation in a system-specific manner, depending on the identity
of the chaperone and the amyloid-forming protein. JB6 has previously
been found to both inhibit primary and secondary nucleation events
of the amyloid fibril formation of amyloid &#x003b2; peptide and polyglutamine
peptide, with a stronger effect on the primary nucleation.<named-content content-type="bibref-group">
<xref rid="ref13" ref-type="bibr"/>&#x02212;<xref rid="ref14" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/>,<xref rid="ref55" ref-type="bibr"/>
</named-content> The effects of JB6 on nucleation are reported to be due to interactions
with oligomers (or the formation of chaperon-client co-oligomers),
which may stabilize the oligomers and prevent their structural conversion
and nucleation to amyloid structures.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/>,<xref rid="ref55" ref-type="bibr"/>
</named-content> Substoichiometric concentrations of the Brichos domain
from proSP-C have been found to strongly interfere with the secondary
nucleation of amyloid &#x003b2; peptide.<xref rid="ref57" ref-type="bibr"/> The cochaperonin prefoldin has also been found to interfere with
the secondary nucleation as well as the elongation of IAPP.<xref rid="ref70" ref-type="bibr"/> A study using a mixture of crystallins showed
suppression of aggregation of &#x003b1;-syn aggregation at pH 5.5, indicating
interaction between crystallins and &#x003b1;-syn fibrils, further suggesting
inhibition of elongation and secondary nucleation steps.<xref rid="ref71" ref-type="bibr"/>
</p><p>The results presented here were performed
under conditions (mildly
acidic pH, quiescent, seeded, nonbinding PEGylated plates) where effects
on secondary nucleation are visible and primary nucleation is a rare
event.<xref rid="ref33" ref-type="bibr"/> The significant and efficient
suppression under these conditions, therefore, indicates that JB6
may interfere with the secondary nucleation events of &#x003b1;-syn
amyloid fibril formation.</p></sec><sec id="sec4.2"><label>4.2</label><title>Evidence of the Formation
of Coaggregates
between &#x003b1;-syn and JB6</title><p>In this study, we have three
lines of evidence for the formation of coaggregates between &#x003b1;-syn
and JB6.</p><p>Firstly, cryo-TEM analysis revealed a striking difference
in the mesoscopic structures of the &#x003b1;-syn aggregates formed
in the presence and absence of JB6 (<xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig"/>
</xref> and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">S13&#x02013;S17</ext-link>). To our knowledge, this is the first structural indication of a
coaggregate of an amyloid-forming protein and a chaperone.</p><p>Secondly,
ThT-negative aggregates are detected in the samples consisting
of &#x003b1;-syn and JB6 at higher molar ratios (&#x02265;3% JB6). This
was detected by visually inspecting centrifuged samples (white pellets, <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>), although aggregates
were clearly seen by cryo-TEM. This suggests that the coaggregates
of &#x003b1;-syn and JB6 are structurally different from the pure &#x003b1;-syn
aggregates.</p><p>Thirdly, we show that JB6 is depleted from solution
upon incubation
in the presence of &#x003b1;-syn (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>), indicating interaction between JB6 and &#x003b1;-syn
and formation of larger structures that sediment upon centrifugation.</p><p>The results presented here are in good agreement with previous
studies of A&#x003b2;42 and JB6 that showed association between JB6
and the fibrils with immunoblots.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref15" ref-type="bibr"/>
</named-content>
</p></sec><sec id="sec4.3"><label>4.3</label><title>Formation of Coaggregates and Increase in
Apparent Solubility</title><p>An increase in apparent solubility of
an amyloid protein in the presence of JB6 has been reported for A&#x003b2;42<xref rid="ref15" ref-type="bibr"/> and is here observed for &#x003b1;-syn. The concentration
of the free &#x003b1;-syn monomer in solution in the end state was found
to positively correlate with the chaperone concentration. This was
seen by comparing the amount of monomer in the supernatant over sedimented
aggregates using different methods: SDS-PAGE, NMR spectroscopy, and
HPLC-MS with absorbance at 280 and 205 nm. Our experimental data thus
provide a second clear case, after A&#x003b2;42,<xref rid="ref15" ref-type="bibr"/> for which the presence of JB6 leads to a significant increase
in amyloid peptide apparent solubility.</p><p>A change in the solubility,
an equilibrium parameter, requires a thermodynamic explanation. One
possible explanation was recently put forward<xref rid="ref9" ref-type="bibr"/> in which the chaperone has a high chemical potential on its own,
which it can reduce upon formation of coaggregates with an amyloid
peptide. The reduction in chaperone chemical potential could thereby
compensate for an increase in the chemical potential of the amyloid
peptide relative to pure aggregates. This would allow the system as
a whole to lower its free energy in spite of an increase in the contribution
from the amyloid peptide and provide a driving force for an increased
amyloid solubility in the presence of the chaperone.<xref rid="ref9" ref-type="bibr"/>
</p><p>As a consequence of the second law of thermodynamics,
a substance
will have equal chemical potential in all phases in a system at thermodynamic
equilibrium. Thus, higher amyloid peptide concentration (higher chemical
potential) in the solution phase could be supported by a higher chemical
potential of the amyloid peptide in the aggregate phase, implying
that these must be altered in some way (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>).<xref rid="ref9" ref-type="bibr"/>
</p><fig position="float" id="fig9" fig-type="figure"><label>9</label><caption><p>Schematic illustration
of the chemical potential of &#x003b1;-synuclein
monomers free in solution (black line), within coaggregates (red line),
and within pure &#x003b1;-syn fibrils. The chemical potential is shown
as a function of the total monomer concentration. The solubility of
&#x003b1;-syn within pure &#x003b1;-syn fibrils (<italic toggle="yes">S</italic>) and
within coaggregates (<italic toggle="yes">S</italic>*) is highlighted with dashed
lines.</p></caption><graphic xlink:href="cn4c00883_0009" id="gr9" position="float"/></fig><p>The chemical potential of free
monomers in solution (&#x003bc;<sub>m</sub>) can be approximated by
its intrinsic energy &#x003b5;<sub>m</sub> and the term coming from
the entropy of mixing:<disp-formula id="ueq1">
<alternatives><graphic xlink:href="cn4c00883_m001.jpg" position="float"/><mml:math id="d1e1405" display="block"><mml:mrow><mml:mspace width="0.25em"/><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="italic">RT</mml:mi><mml:mspace width="0.25em"/><mml:mi>ln</mml:mi><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives>
</disp-formula>where [m] is the concentration of monomers
in solution.</p><p>Amyloid fibrils are large and highly ordered structures
and can
therefore be seen as a solid phase. The contribution of translation
entropy is minimal, and the chemical potential of monomers in fibrils
(mf) can be approximated to equal the intrinsic energy:<disp-formula id="ueq2">
<alternatives><graphic xlink:href="cn4c00883_m002.jpg" position="float"/><mml:math id="d1e1435" display="block"><mml:mrow><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi>mf</mml:mi></mml:msub></mml:mrow></mml:math></alternatives>
</disp-formula>
</p><p>The chemical potential of the free monomers in solution is
thus
concentration-dependent, and for monomers in fibrils, concentration-independent
(<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>). At equilibrium,
the chemical potential of the monomers in solution is equal to that
of the monomers in the fibrils. The solubility, <italic toggle="yes">S</italic>, is equal to the concentration of monomers in solution at equilibrium
and can thus be written as<disp-formula id="ueq3">
<alternatives><graphic xlink:href="cn4c00883_m003.jpg" position="float"/><mml:math id="d1e1460" display="block"><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi>mf</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub></mml:mrow><mml:mi mathvariant="italic">RT</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:math></alternatives>
</disp-formula>
</p><p>The solubility of the amyloid monomers is therefore dependent
on
the stability of the fibrils formed, consistent with a previous study
of two chemically identical &#x003b1;-syn fibrils of different morphology,
with &#x003b1;-syn displaying a lower solubility in the presence of
the more stable fibrils.<xref rid="ref72" ref-type="bibr"/>
</p><p>The NMR
spectra do not report on any significant binding between
&#x003b1;-syn monomers and JB6 (see <xref rid="sec3.4" ref-type="sec">Section <xref rid="sec3.4" ref-type="sec"/>
</xref>) in agreement with previous reports.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>,<xref rid="ref48" ref-type="bibr"/>
</named-content> Similarly, no signs of binding between &#x003b1;-syn monomers and
the 14-3-3-<italic toggle="yes">t</italic> chaperone have been detected.<xref rid="ref73" ref-type="bibr"/> Therefore, in a dilute system, we assume that
the intrinsic energy of the monomer is unaltered in the presence of
JB6. The chemical potential of &#x003b1;-syn monomer in solution in
the presence of the chaperone (JB6) can thus be written as<disp-formula id="ueq4">
<alternatives><graphic xlink:href="cn4c00883_m004.jpg" position="float"/><mml:math id="d1e1503" display="block"><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mo accent="false">*</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="italic">RT</mml:mi><mml:mspace width="0.25em"/><mml:mi>ln</mml:mi><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msup><mml:mi mathvariant="normal">m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></alternatives>
</disp-formula>where m*
denotes the amyloid protein monomer
in the presence of a chaperone. At equilibrium, the chemical potential
of monomers free in solution must be equal to the chemical potential
of the monomers within the coaggregates:<disp-formula id="ueq5">
<alternatives><graphic xlink:href="cn4c00883_m005.jpg" position="float"/><mml:math id="d1e1535" display="block"><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mo accent="false">*</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x003bc;</mml:mi><mml:mrow><mml:mi>mf</mml:mi><mml:mo accent="false">*</mml:mo></mml:mrow></mml:msub></mml:math></alternatives>
</disp-formula>The solubility in the presence of JB6, <italic toggle="yes">S</italic>*, can thus be written as<disp-formula id="ueq6">
<alternatives><graphic xlink:href="cn4c00883_m006.jpg" position="float"/><mml:math id="d1e1557" display="block"><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mrow><mml:mi>mf</mml:mi><mml:mo accent="false">*</mml:mo></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mo accent="false">*</mml:mo></mml:mrow></mml:msub></mml:mrow><mml:mi mathvariant="italic">RT</mml:mi></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:math></alternatives>
</disp-formula>
</p><p>The
results presented in this paper indicate that the apparent
solubility of &#x003b1;-syn increases in the presence of the chaperone:<disp-formula id="ueq7">
<alternatives><graphic xlink:href="cn4c00883_m007.jpg" position="float"/><mml:math id="d1e1592" display="block"><mml:msup><mml:mi>S</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>&#x0003e;</mml:mo><mml:mi>S</mml:mi></mml:math></alternatives>
</disp-formula>which suggests that the intrinsic energy of
the monomer in the fibrils formed in the presence of chaperone is
higher than the intrinsic energy of the free monomer in fibrils formed
from &#x003b1;-syn alone.<disp-formula id="ueq8">
<alternatives><graphic xlink:href="cn4c00883_m008.jpg" position="float"/><mml:math id="d1e1602" display="block"><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mo accent="false">*</mml:mo></mml:mrow></mml:msub><mml:mo>&#x0003e;</mml:mo><mml:msub><mml:mi>&#x003f5;</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow></mml:msub></mml:math></alternatives>
</disp-formula>This further implies that
the aggregates formed
in the presence and absence of the chaperone are of different structures
with different stability. This is supported by our cryo-TEM results
showing remarkably different structures for the fibrils formed in
the absence and presence of JB6, indicating the formation of coaggregates
in the latter case.</p><p>The increased apparent solubility of &#x003b1;-syn
in the presence
of JB6 thus suggests that the coaggregates are less stable structures
compared to the pure &#x003b1;-syn fibrils.</p></sec><sec id="sec4.4"><label>4.4</label><title>The Driving
Force for Coaggregate Formation
between &#x003b1;-syn and JB6</title><p>What would be the driving force
for the system to form the coaggregates in which the &#x003b1;-syn chemical
potential is increased compared to pure &#x003b1;-syn aggregates? This
question might be explained by the high chemical potential of the
chaperone alone (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>) and the requirement for the system as a whole to lower its
free energy for a process to happen. At equilibrium, the system has
reached the lowest possible total free energy. In the case of the
chaperone, the formation of coaggregates results in a decrease in
free energy that is greater than the increase in free energy of &#x003b1;-syn,
causing the process of forming coaggregates of &#x003b1;-syn and JB6
to be favorable (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>). Thus, the free energy of a system consisting of coaggregates
is lower than for a system consisting of pure &#x003b1;-syn coexisting
with JB6 (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>).<xref rid="ref9" ref-type="bibr"/> A comparable phenomenon is observed
and utilized within pharmaceutical science, where an increase in solubility
of a drug molecule is obtained by cocrystallization with another compound
of high chemical potential, forming a structurally different cocrystal
that is less stable than the pure drug crystal. The cocrystallization
results in the system having overall lower free energy, where the
energy loss of the drug molecule is compensated by the energy gain
of the other compound.<named-content content-type="bibref-group">
<xref rid="ref74" ref-type="bibr"/>,<xref rid="ref75" ref-type="bibr"/>
</named-content> If on the contrary, the chaperone
would bind to fibrils after their formation, as in the case of Brichos
and prefoldin,<named-content content-type="bibref-group">
<xref rid="ref57" ref-type="bibr"/>,<xref rid="ref70" ref-type="bibr"/>
</named-content> such coating would rather stabilize
the fibrils, and could only maintain or reduce the solubility.</p><fig position="float" id="fig10" fig-type="figure"><label>10</label><caption><p>Thermodynamics
behind the formation of coaggregates of &#x003b1;-syn
and JB6. (A) Free energy diagrams of closed systems of &#x003b1;-syn
alone (i), JB6 alone (ii), and &#x003b1;-syn + JB6 (iii, iv). Due to
the high free energy of the chaperone alone (ii), the formation of
coaggregates (iv) of &#x003b1;-syn and JB6 is thermodynamically more
favorable than the coexistence of pure &#x003b1;-syn fibrils and JB6
(iii). The formation of coaggregates (iv) results in the decrease
in free energy of JB6 being greater than the increase in free energy
of &#x003b1;-syn, causing the total free energy of the system to be
lower. The higher free energy of &#x003b1;-syn within a coaggregate
(iv) than within a pure &#x003b1;-syn fibril (i) can explain the increase
in solubility of &#x003b1;-syn in the presence of chaperone (iv). (B)
Free energy diagram showing that formation of coaggregates (iv) from
a solution consisting of &#x003b1;-syn and JB6 (v) is the most energetically
favorable state, despite the solubility of &#x003b1;-syn increasing.</p></caption><graphic xlink:href="cn4c00883_0010" id="gr10" position="float"/></fig></sec></sec><sec id="sec4.5"><label>5</label><title>Conclusions</title><p>The
results of this study show that the fibril formation of &#x003b1;-syn
is suppressed by JB6 at low stoichiometric ratios (0.0004:1 molar
ratio of JB6 to &#x003b1;-syn) in vitro at mildly acidic pH and low
seed concentration, indicating that JB6 may interfere with the secondary
nucleation events of &#x003b1;-syn amyloid fibril formation. In the
presence of JB6, &#x003b1;-syn forms coaggregates of altered structure
and stability, resulting in an increase in the apparent solubility
compared to pure &#x003b1;-syn fibrils. A solubility increase in the
presence of a chaperone can be explained by the high chemical potential
of the chaperone alone, making it thermodynamically more favorable
to form a coaggregate between &#x003b1;-syn and JB6. This free energy
gain is greater than the free energy loss for &#x003b1;-syn, lowering
the free energy of the system as a whole.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data"><media xlink:href="cn4c00883_si_001.pdf"/></supplementary-material></sec></body><back><ack id="ACK-d14e1543-autogenerated"><p>The authors thank Matthijs Oosterhuis for help with the initial
aggregation experiments, Crispin Hetherington for help with cryo-TEM,
and Katja Bernfur for assistance with mass spectrometry, expression,
and purification. This work was supported by the Swedish Research
Council (VR 2015-00134 to S.L.), European Research Council (ERC 101097824
to S.L.), Knut and Alice Wallenberg Foundation (KAW 2022-0059 to S.L.,
U.O.), and NanoLund (T.P.).</p></ack><notes id="notes-3" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acschemneuro.4c00883?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acschemneuro.4c00883</ext-link>.<list list-type="simple" id="silist"><list-item><p>DNA and protein sequence
of wild-type &#x003b1;-syn; verification
of the expression of &#x003b1;-syn; purification of &#x003b1;-syn; DNA
and protein sequence of DNAJB6b (JB6); purity of DNAJB6b batches used
in this study; size exclusion and kinetic analysis; solubility measurements
of &#x003b1;-syn with JB6 at pH 5.5; NMR experiments at low &#x003b1;-syn/JB6
molar ratio; adsorption of JB6 to NMR tubes; effect of JB6 on residue
resolved signals of free &#x003b1;-syn monomer measured by NMR spectroscopy;
cryo-TEM of &#x003b1;-syn in the presence of JB6 at pH 4.5; cryo-TEM
and corresponding kinetics at pH 5.5; and JB6 in supernatant at pH
4.5 (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acschemneuro.4c00883/suppl_file/cn4c00883_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-1" notes-type="author-contributions"><label>&#x02225;</label><p>T.P. and
J.G. contributed equally. The manuscript was written through
contributions of all authors. Conceptualization and design of the
study: T.P., J.G., U.O., C.E., and S.L.; Methodology: T.P., J.G.,
U.O., C.E., and S.L.: Investigation: T.P., J.G., S.L., D.T., and J.W.;
Formal analysis: T.P., J.G., U.O., C.E., and S.L.; Writing&#x0e5f8;original
draft: T.P., J.G., U.O., and S.L.; Writing&#x0e5f8;review and editing:
T.P., J.G., D.T., J.W., U.O., C.E., and S.L.; Supervision: U.O., C.E.,
and S.L. All authors have given approval to the final version of the
manuscript.</p></notes><notes id="notes-2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name><surname>Sipe</surname><given-names>J. D.</given-names></name><name><surname>Benson</surname><given-names>M. D.</given-names></name><name><surname>Buxbaum</surname><given-names>J. N.</given-names></name><name><surname>Ikeda</surname><given-names>S. I.</given-names></name><name><surname>Merlini</surname><given-names>G.</given-names></name><name><surname>Saraiva</surname><given-names>M. J.</given-names></name><name><surname>Westermark</surname><given-names>P.</given-names></name><article-title>Amyloid fibril protein nomenclature:
2012 recommendations from the Nomenclature Committee of the International
Society of Amyloidosis</article-title><source>Amyloid</source><year>2012</year><volume>19</volume><fpage>167</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.3109/13506129.2012.734345</pub-id><pub-id pub-id-type="pmid">23113696</pub-id>
</element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name><surname>Lansbury</surname><given-names>P. T.</given-names></name><name><surname>Lashuel</surname><given-names>H. A.</given-names></name><article-title>A century-old debate
on protein aggregation and neurodegeneration
enters the clinic</article-title><source>Nature</source><year>2006</year><volume>443</volume><fpage>774</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1038/nature05290</pub-id><pub-id pub-id-type="pmid">17051203</pub-id>
</element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name><surname>Chiti</surname><given-names>F.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><article-title>Protein misfolding,
functional amyloid, and human disease</article-title><source>Annu.
Rev. Biochem.</source><year>2006</year><volume>75</volume><fpage>333</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.75.101304.123901</pub-id><pub-id pub-id-type="pmid">16756495</pub-id>
</element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name><surname>Bukau</surname><given-names>B.</given-names></name><name><surname>Weissman</surname><given-names>J.</given-names></name><name><surname>Horwich</surname><given-names>A.</given-names></name><article-title>Molecular Chaperones and Protein
Quality Control</article-title><source>Cell</source><year>2006</year><volume>125</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.04.014</pub-id><pub-id pub-id-type="pmid">16678092</pub-id>
</element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name><surname>Lee</surname><given-names>S.-Y.</given-names></name><name><surname>Tsai</surname><given-names>F. T.</given-names></name><article-title>Molecular chaperones
in protein quality control</article-title><source>BMB Rep.</source><year>2005</year><volume>38</volume><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2005.38.3.259</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name><surname>Cortez</surname><given-names>L.</given-names></name><name><surname>Sim</surname><given-names>V.</given-names></name><article-title>The therapeutic potential
of chemical chaperones in protein folding
diseases</article-title><source>Prion</source><year>2014</year><volume>8</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.4161/pri.28938</pub-id><pub-id pub-id-type="pmid">24818993</pub-id>
</element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name><surname>Chaplot</surname><given-names>K.</given-names></name><name><surname>Jarvela</surname><given-names>T. S.</given-names></name><name><surname>Lindberg</surname><given-names>I.</given-names></name><article-title>Secreted Chaperones
in Neurodegeneration</article-title><source>Front. Aging Neurosci.</source><year>2020</year><volume>12</volume><elocation-id>268</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2020.00268</pub-id><pub-id pub-id-type="pmid">33192447</pub-id>
</element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name><surname>Sinnige</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>A.</given-names></name><name><surname>Morimoto</surname><given-names>R. I.</given-names></name><article-title>Challenging Proteostasis: Role of the Chaperone Network
to Control Aggregation-Prone Proteins in Human Disease</article-title><source>Adv. Exp. Med. Biol.</source><year>2020</year><volume>1243</volume><fpage>53</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-40204-4_4</pub-id><pub-id pub-id-type="pmid">32297211</pub-id>
</element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Thalberg</surname><given-names>K.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><article-title>The unhappy chaperone</article-title><source>QRB Discovery</source><year>2021</year><volume>2</volume><elocation-id>e7</elocation-id><pub-id pub-id-type="doi">10.1017/qrd.2021.5</pub-id><pub-id pub-id-type="pmid">37529680</pub-id>
</element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name><surname>Hageman</surname><given-names>J.</given-names></name><name><surname>Rujano</surname><given-names>M. A.</given-names></name><name><surname>van Waarde</surname><given-names>M. A.</given-names></name><name><surname>Kakkar</surname><given-names>V.</given-names></name><name><surname>Dirks</surname><given-names>R. P.</given-names></name><name><surname>Govorukhina</surname><given-names>N.</given-names></name><name><surname>Oosterveld-Hut</surname><given-names>H. M.</given-names></name><name><surname>Lubsen</surname><given-names>N. H.</given-names></name><name><surname>Kampinga</surname><given-names>H. H.</given-names></name><article-title>A DNAJB
Chaperone Subfamily with HDAC-Dependent Activities Suppresses Toxic
Protein Aggregation</article-title><source>Mol. Cell</source><year>2010</year><volume>37</volume><fpage>355</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.01.001</pub-id><pub-id pub-id-type="pmid">20159555</pub-id>
</element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name><surname>Nillegoda</surname><given-names>N. B.</given-names></name><name><surname>Kirstein</surname><given-names>J.</given-names></name><name><surname>Szlachcic</surname><given-names>A.</given-names></name><name><surname>Berynskyy</surname><given-names>M.</given-names></name><name><surname>Stank</surname><given-names>A.</given-names></name><name><surname>Stengel</surname><given-names>F.</given-names></name><name><surname>Arnsburg</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Scior</surname><given-names>A.</given-names></name><name><surname>Aebersold</surname><given-names>R.</given-names></name><name><surname>Guilbride</surname><given-names>D. L.</given-names></name><name><surname>Wade</surname><given-names>R. C.</given-names></name><name><surname>Morimoto</surname><given-names>R. I.</given-names></name><name><surname>Mayer</surname><given-names>M. P.</given-names></name><name><surname>Bukau</surname><given-names>B.</given-names></name><article-title>Crucial HSP70
co-chaperone complex unlocks metazoan protein disaggregation</article-title><source>Nature</source><year>2015</year><volume>524</volume><fpage>247</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nature14884</pub-id><pub-id pub-id-type="pmid">26245380</pub-id>
</element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Carroni</surname><given-names>M.</given-names></name><name><surname>Nussbaum-Krammer</surname><given-names>C.</given-names></name><name><surname>Mogk</surname><given-names>A.</given-names></name><name><surname>Nillegoda</surname><given-names>N. B.</given-names></name><name><surname>Szlachcic</surname><given-names>A.</given-names></name><name><surname>Guilbride</surname><given-names>D. L.</given-names></name><name><surname>Saibil</surname><given-names>H. R.</given-names></name><name><surname>Mayer</surname><given-names>M. P.</given-names></name><name><surname>Bukau</surname><given-names>B.</given-names></name><article-title>Human Hsp70 Disaggregase Reverses Parkinson&#x02019;s-Linked <italic toggle="yes">&#x003b1;</italic>-Synuclein Amyloid Fibrils</article-title><source>Mol. Cell</source><year>2015</year><volume>59</volume><fpage>781</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.07.012</pub-id><pub-id pub-id-type="pmid">26300264</pub-id>
</element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name><surname>M&#x000e5;nsson</surname><given-names>C.</given-names></name><name><surname>Kakkar</surname><given-names>V.</given-names></name><name><surname>Monsellier</surname><given-names>E.</given-names></name><name><surname>Sourigues</surname><given-names>Y.</given-names></name><name><surname>H&#x000e4;rmark</surname><given-names>J.</given-names></name><name><surname>Kampinga</surname><given-names>H. H.</given-names></name><name><surname>Melki</surname><given-names>R.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><article-title>DNAJB6 is
a peptide-binding chaperone which can suppress amyloid fibrillation
of polyglutamine peptides at substoichiometric molar ratios</article-title><source>Cell Stress Chaperones</source><year>2014</year><volume>19</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1007/s12192-013-0448-5</pub-id><pub-id pub-id-type="pmid">23904097</pub-id>
</element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name><surname>M&#x000e5;nsson</surname><given-names>C.</given-names></name><name><surname>Arosio</surname><given-names>P.</given-names></name><name><surname>Hussein</surname><given-names>R.</given-names></name><name><surname>Kampinga</surname><given-names>H. H.</given-names></name><name><surname>Hashem</surname><given-names>R. M.</given-names></name><name><surname>Boelens</surname><given-names>W. C.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><article-title>Interaction of the molecular chaperone
DNAJB6 with
growing amyloid-beta 42 (A<italic toggle="yes">&#x003b2;</italic>42) aggregates leads
to sub-stoichiometric inhibition of amyloid formation</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>31066</fpage><lpage>31076</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.595124</pub-id><pub-id pub-id-type="pmid">25217638</pub-id>
</element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name><surname>M&#x000e5;nsson</surname><given-names>C.</given-names></name><name><surname>Van Cruchten</surname><given-names>R. T.</given-names></name><name><surname>Weininger</surname><given-names>U.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Cukalevski</surname><given-names>R.</given-names></name><name><surname>Arosio</surname><given-names>P.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><name><surname>Knowles</surname><given-names>T.</given-names></name><name><surname>Akke</surname><given-names>M.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><article-title>Conserved S/T Residues of the Human
Chaperone DNAJB6 Are Required for Effective Inhibition of A<italic toggle="yes">&#x003b2;</italic>42 Amyloid Fibril Formation</article-title><source>Biochemistry</source><year>2018</year><volume>57</volume><fpage>4891</fpage><lpage>4892</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.8b00353</pub-id><pub-id pub-id-type="pmid">30024736</pub-id>
</element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name><surname>Gillis</surname><given-names>J.</given-names></name><name><surname>Schipper-Krom</surname><given-names>S.</given-names></name><name><surname>Juenemann</surname><given-names>K.</given-names></name><name><surname>Gruber</surname><given-names>A.</given-names></name><name><surname>Coolen</surname><given-names>S.</given-names></name><name><surname>Van Den Nieuwendijk</surname><given-names>R.</given-names></name><name><surname>Van Veen</surname><given-names>H.</given-names></name><name><surname>Overkleeft</surname><given-names>H.</given-names></name><name><surname>Goedhart</surname><given-names>J.</given-names></name><name><surname>Kampinga</surname><given-names>H. H.</given-names></name><name><surname>Reits</surname><given-names>E. A.</given-names></name><article-title>The DNAJB6 and DNAJB8
protein chaperones prevent intracellular aggregation of polyglutamine
peptides</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>17225</fpage><lpage>17237</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.421685</pub-id><pub-id pub-id-type="pmid">23612975</pub-id>
</element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name><surname>&#x000d6;sterlund</surname><given-names>N.</given-names></name><name><surname>Frankel</surname><given-names>R.</given-names></name><name><surname>Carlsson</surname><given-names>A.</given-names></name><name><surname>Thacker</surname><given-names>D.</given-names></name><name><surname>Karlsson</surname><given-names>M.</given-names></name><name><surname>Matus</surname><given-names>V.</given-names></name><name><surname>Gr&#x000e4;slund</surname><given-names>A.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>The C-terminal domain of the antiamyloid
chaperone DNAJB6 binds to
amyloid-<italic toggle="yes">&#x003b2;</italic> peptide fibrils and inhibits secondary
nucleation</article-title><source>J. Biol. Chem.</source><year>2023</year><volume>299</volume><elocation-id>105317</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2023.105317</pub-id><pub-id pub-id-type="pmid">37797698</pub-id>
</element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name><surname>Liberek</surname><given-names>K.</given-names></name><name><surname>Lewandowska</surname><given-names>A.</given-names></name><name><surname>Zitkiewicz</surname><given-names>S.</given-names></name><article-title>Chaperones in control of protein
disaggregation</article-title><source>EMBO J.</source><year>2008</year><volume>27</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601970</pub-id><pub-id pub-id-type="pmid">18216875</pub-id>
</element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name><surname>George</surname><given-names>J. M.</given-names></name><article-title>The synucleins</article-title><source>Genome Biol.</source><year>2001</year><volume>3</volume><elocation-id>reviews3002.1</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2001-3-1-reviews3002</pub-id><pub-id pub-id-type="pmid">11806835</pub-id>
</element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name><surname>Burr&#x000e9;</surname><given-names>J.</given-names></name><article-title>The synaptic
function of <italic toggle="yes">&#x003b1;</italic>-synuclein</article-title><source>J. Parkinson&#x02019;s Dis.</source><year>2015</year><volume>5</volume><fpage>699</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.3233/JPD-150642</pub-id><pub-id pub-id-type="pmid">26407041</pub-id>
</element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name><surname>Ulmer</surname><given-names>T. S.</given-names></name><name><surname>Bax</surname><given-names>A.</given-names></name><name><surname>Cole</surname><given-names>N. B.</given-names></name><name><surname>Nussbaum</surname><given-names>R. L.</given-names></name><article-title>Structure and Dynamics of Micelle-bound
Human <italic toggle="yes">&#x003b1;</italic>-Synuclein</article-title><source>J.
Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>9595</fpage><lpage>9603</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411805200</pub-id><pub-id pub-id-type="pmid">15615727</pub-id>
</element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name><surname>Cho</surname><given-names>M. K.</given-names></name><name><surname>Nodet</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>H. Y.</given-names></name><name><surname>Jensen</surname><given-names>M. R.</given-names></name><name><surname>Bernado</surname><given-names>P.</given-names></name><name><surname>Fernandez</surname><given-names>C. O.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Blackledge</surname><given-names>M.</given-names></name><name><surname>Zweckstetter</surname><given-names>M.</given-names></name><article-title>Structural
characterization of <italic toggle="yes">&#x003b1;</italic>-synuclein in an aggregation
prone state</article-title><source>Protein
Sci.</source><year>2009</year><volume>18</volume><fpage>1840</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1002/pro.194</pub-id><pub-id pub-id-type="pmid">19554627</pub-id>
</element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name><surname>Croke</surname><given-names>R. L.</given-names></name><name><surname>Patil</surname><given-names>S. M.</given-names></name><name><surname>Quevreaux</surname><given-names>J.</given-names></name><name><surname>Kendall</surname><given-names>Da.</given-names></name><name><surname>Alexandrescu</surname><given-names>aT.</given-names></name><article-title>NMR determination
of pKa values in <italic toggle="yes">&#x003b1;</italic>-synuclein</article-title><source>Protein Sci.</source><year>2011</year><volume>20</volume><fpage>256</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1002/pro.556</pub-id><pub-id pub-id-type="pmid">21280118</pub-id>
</element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name><surname>Makasewicz</surname><given-names>K.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Sparr</surname><given-names>E.</given-names></name><article-title>Interplay of <italic toggle="yes">&#x003b1;</italic>-synuclein with Lipid Membranes: Cooperative Adsorption, Membrane
Remodeling and Coaggregation</article-title><source>JACS Au</source><year>2024</year><volume>4</volume><fpage>1250</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1021/jacsau.3c00579</pub-id><pub-id pub-id-type="pmid">38665673</pub-id>
</element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name><surname>Cheng</surname><given-names>F.</given-names></name><name><surname>Vivacqua</surname><given-names>G.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><article-title>The role of
alpha-synuclein in neurotransmission
and synaptic plasticity</article-title><source>J. Chem. Neuroanat.</source><year>2011</year><volume>42</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2010.12.001</pub-id><pub-id pub-id-type="pmid">21167933</pub-id>
</element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name><surname>Serratos</surname><given-names>I. N.</given-names></name><name><surname>Hern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>E.</given-names></name><name><surname>Campos</surname><given-names>C.</given-names></name><name><surname>Aschner</surname><given-names>M.</given-names></name><name><surname>Santamar&#x000ed;a</surname><given-names>A.</given-names></name><article-title>An Update
on the Critical Role of <italic toggle="yes">&#x003b1;</italic>-Synuclein in Parkinson&#x02019;s
Disease and Other Synucleinopathies:
from Tissue to Cellular and Molecular Levels</article-title><source>Mol. Neurobiol.</source><year>2022</year><volume>59</volume><fpage>620</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1007/s12035-021-02596-3</pub-id><pub-id pub-id-type="pmid">34750787</pub-id>
</element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name><surname>Bernal-Conde</surname><given-names>L. D.</given-names></name><name><surname>Ramos-Acevedo</surname><given-names>R.</given-names></name><name><surname>Reyes-Hern&#x000e1;ndez</surname><given-names>M. A.</given-names></name><name><surname>Balbuena-Olvera</surname><given-names>A. J.</given-names></name><name><surname>Morales-Moreno</surname><given-names>I. D.</given-names></name><name><surname>Arg&#x000fc;ero-S&#x000e1;nchez</surname><given-names>R.</given-names></name><name><surname>Sch&#x000fc;le</surname><given-names>B.</given-names></name><name><surname>Guerra-Crespo</surname><given-names>M.</given-names></name><article-title>Alpha-Synuclein Physiology and Pathology:
A Perspective on Cellular Structures and Organelles</article-title><source>Front. Neurosci.</source><year>2020</year><volume>13</volume><elocation-id>1399</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2019.01399</pub-id><pub-id pub-id-type="pmid">32038126</pub-id>
</element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name><surname>Goedert</surname><given-names>M.</given-names></name><article-title>Alpha-synuclein
and neurodegenerative diseases</article-title><source>Nat. Rev. Neurosci.</source><year>2001</year><volume>2</volume><fpage>492</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/35081564</pub-id><pub-id pub-id-type="pmid">11433374</pub-id>
</element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name><surname>Rabe</surname><given-names>M.</given-names></name><name><surname>Soragni</surname><given-names>A.</given-names></name><name><surname>Reynolds</surname><given-names>N. P.</given-names></name><name><surname>Verdes</surname><given-names>D.</given-names></name><name><surname>Liverani</surname><given-names>E.</given-names></name><name><surname>Riek</surname><given-names>R.</given-names></name><name><surname>Seeger</surname><given-names>S.</given-names></name><article-title>On-surface
aggregation of <italic toggle="yes">&#x003b1;</italic>-synuclein at nanomolar concentrations
results in
two distinct growth mechanisms</article-title><source>ACS Chem. Neurosci.</source><year>2013</year><volume>4</volume><fpage>408</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1021/cn3001312</pub-id><pub-id pub-id-type="pmid">23509977</pub-id>
</element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name><surname>Campioni</surname><given-names>S.</given-names></name><name><surname>Carret</surname><given-names>G.</given-names></name><name><surname>Jordens</surname><given-names>S.</given-names></name><name><surname>Nicoud</surname><given-names>L.</given-names></name><name><surname>Mezzenga</surname><given-names>R.</given-names></name><name><surname>Riek</surname><given-names>R.</given-names></name><article-title>The presence of an
air-water interface affects formation and elongation
of <italic toggle="yes">&#x003b1;</italic>-synuclein fibrils</article-title><source>J. Am. Chem. Soc.</source><year>2014</year><volume>136</volume><fpage>2866</fpage><lpage>2875</lpage><pub-id pub-id-type="doi">10.1021/ja412105t</pub-id><pub-id pub-id-type="pmid">24460028</pub-id>
</element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name><surname>V&#x000e1;cha</surname><given-names>R.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Lund</surname><given-names>M.</given-names></name><article-title>Surface effects on aggregation kinetics
of amyloidogenic peptides</article-title><source>J. Am. Chem. Soc.</source><year>2014</year><volume>136</volume><fpage>11776</fpage><lpage>11782</lpage><pub-id pub-id-type="doi">10.1021/ja505502e</pub-id><pub-id pub-id-type="pmid">25068615</pub-id>
</element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name><surname>Pronchik</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Giurleo</surname><given-names>J. T.</given-names></name><name><surname>Talaga</surname><given-names>D. S.</given-names></name><article-title>In vitro formation of amyloid from <italic toggle="yes">&#x003b1;</italic>-synuclein is dominated by reactions at hydrophobic
interfaces</article-title><source>J. Am. Chem. Soc.</source><year>2010</year><volume>132</volume><fpage>9797</fpage><lpage>9803</lpage><pub-id pub-id-type="doi">10.1021/ja102896h</pub-id><pub-id pub-id-type="pmid">20578692</pub-id>
</element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name><surname>Buell</surname><given-names>A. K.</given-names></name><name><surname>Galvagnion</surname><given-names>C.</given-names></name><name><surname>Gaspar</surname><given-names>R.</given-names></name><name><surname>Sparr</surname><given-names>E.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><name><surname>Knowles</surname><given-names>T. P. J.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><article-title>Solution conditions
determine the relative importance of nucleation and growth processes
in <italic toggle="yes">&#x003b1;</italic>-synuclein aggregation</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2014</year><volume>111</volume><fpage>7671</fpage><lpage>7676</lpage><pub-id pub-id-type="doi">10.1073/pnas.1315346111</pub-id><pub-id pub-id-type="pmid">24817693</pub-id>
</element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name><surname>Uversky</surname><given-names>V. N.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Fink</surname><given-names>A. L.</given-names></name><article-title>Evidence
for a Partially Folded Intermediate in <italic toggle="yes">&#x003b1;</italic>-Synuclein
Fibril Formation</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>10737</fpage><lpage>10744</lpage><pub-id pub-id-type="doi">10.1074/jbc.M010907200</pub-id><pub-id pub-id-type="pmid">11152691</pub-id>
</element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name><surname>Gaspar</surname><given-names>R.</given-names></name><name><surname>Meisl</surname><given-names>G.</given-names></name><name><surname>Buell</surname><given-names>A. K.</given-names></name><name><surname>Young</surname><given-names>L.</given-names></name><name><surname>Kaminski</surname><given-names>C. F.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Sparr</surname><given-names>E.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>Acceleration of <italic toggle="yes">&#x003b1;</italic>-synuclein aggregation</article-title><source>Amyloid</source><year>2017</year><volume>24</volume><fpage>20</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/13506129.2017.1292904</pub-id><pub-id pub-id-type="pmid">28434341</pub-id>
</element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name><surname>Wu</surname><given-names>M. M.</given-names></name><name><surname>Grabe</surname><given-names>M.</given-names></name><name><surname>Adams</surname><given-names>S.</given-names></name><name><surname>Tsien</surname><given-names>R. Y.</given-names></name><name><surname>Moore</surname><given-names>H. P. H.</given-names></name><name><surname>Machen</surname><given-names>T. E.</given-names></name><article-title>Mechanisms of pH Regulation in the
Regulated Secretory
Pathway</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>33027</fpage><lpage>33035</lpage><pub-id pub-id-type="doi">10.1074/jbc.M103917200</pub-id><pub-id pub-id-type="pmid">11402049</pub-id>
</element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name><surname>Casey</surname><given-names>J. R.</given-names></name><name><surname>Grinstein</surname><given-names>S.</given-names></name><name><surname>Orlowski</surname><given-names>J.</given-names></name><article-title>Sensors and regulators of intracellular
pH</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2010</year><volume>11</volume><fpage>50</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nrm2820</pub-id><pub-id pub-id-type="pmid">19997129</pub-id>
</element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name><surname>Colomer</surname><given-names>V.</given-names></name><name><surname>Kicska</surname><given-names>G. A.</given-names></name><name><surname>Rindler</surname><given-names>M. J.</given-names></name><article-title>Secretory
granule content proteins
and the luminal domains of granule membrane proteins aggregate in
vitro at mildly acidic pH</article-title><source>J. Biol. Chem.</source><year>1996</year><volume>271</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.1.48</pub-id><pub-id pub-id-type="pmid">8550606</pub-id>
</element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name><surname>Deshayes</surname><given-names>N.</given-names></name><name><surname>Arkan</surname><given-names>S.</given-names></name><name><surname>Hansen</surname><given-names>C.</given-names></name><article-title>The molecular
chaperone DNAJB6, but
Not DNAJB1, suppresses the seeded aggregation of alpha-synuclein in
cells</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>4495</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20184495</pub-id><pub-id pub-id-type="pmid">31514384</pub-id>
</element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name><surname>Zarouchlioti</surname><given-names>C.</given-names></name><name><surname>Parfitt</surname><given-names>D. A.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Gittings</surname><given-names>L. M.</given-names></name><name><surname>Cheetham</surname><given-names>M. E.</given-names></name><article-title>DNAJ Proteins
in neurodegeneration: Essential and protective factors</article-title><source>Philos. Trans. R. Soc., B</source><year>2018</year><volume>373</volume><elocation-id>20160534</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2016.0534</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name><surname>Qiu</surname><given-names>X. B.</given-names></name><name><surname>Shao</surname><given-names>Y. M.</given-names></name><name><surname>Miao</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><article-title>The diversity of the
DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones</article-title><source>Cell. Mol. Life Sci.</source><year>2006</year><volume>63</volume><fpage>2560</fpage><lpage>2570</lpage><pub-id pub-id-type="doi">10.1007/s00018-006-6192-6</pub-id><pub-id pub-id-type="pmid">16952052</pub-id>
</element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name><surname>Durrenberger</surname><given-names>P. F.</given-names></name><name><surname>Filiou</surname><given-names>M. D.</given-names></name><name><surname>Moran</surname><given-names>L. B.</given-names></name><name><surname>Michael</surname><given-names>G. J.</given-names></name><name><surname>Novoselov</surname><given-names>S.</given-names></name><name><surname>Cheetham</surname><given-names>M. E.</given-names></name><name><surname>Clark</surname><given-names>P.</given-names></name><name><surname>Pearce</surname><given-names>R. K.</given-names></name><name><surname>Graeber</surname><given-names>M. B.</given-names></name><article-title>DnaJB6
is present in the core of Lewy bodies and is highly up-regulated in
Parkinsonian astrocytes</article-title><source>J. Neurosci. Res.</source><year>2009</year><volume>87</volume><fpage>238</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1002/jnr.21819</pub-id><pub-id pub-id-type="pmid">18711724</pub-id>
</element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name><surname>Hentze</surname><given-names>J.</given-names></name><name><surname>Folke</surname><given-names>J.</given-names></name><name><surname>Aznar</surname><given-names>S.</given-names></name><name><surname>Nyeng</surname><given-names>P.</given-names></name><name><surname>Brudek</surname><given-names>T.</given-names></name><name><surname>Hansen</surname><given-names>C.</given-names></name><article-title>DNAJB6 is expressed
in neurons and oligodendrocytes
of the human brain</article-title><source>Glia</source><year>2024</year><volume>72</volume><fpage>2313</fpage><pub-id pub-id-type="doi">10.1002/glia.24615</pub-id><pub-id pub-id-type="pmid">39228066</pub-id>
</element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name><surname>Arkan</surname><given-names>S.</given-names></name><name><surname>Ljungberg</surname><given-names>M.</given-names></name><name><surname>Kirik</surname><given-names>D.</given-names></name><name><surname>Hansen</surname><given-names>C.</given-names></name><article-title>DNAJB6 suppresses alpha-synuclein
induced pathology in an animal model of Parkinson&#x02019;s disease</article-title><source>Neurobiol. Dis</source><year>2021</year><volume>158</volume><elocation-id>105477</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2021.105477</pub-id><pub-id pub-id-type="pmid">34390836</pub-id>
</element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name><surname>Aprile</surname><given-names>F. A.</given-names></name><name><surname>K&#x000e4;llstig</surname><given-names>E.</given-names></name><name><surname>Limorenko</surname><given-names>G.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><name><surname>Ron</surname><given-names>D.</given-names></name><name><surname>Hansen</surname><given-names>C.</given-names></name><article-title>The molecular chaperones
DNAJB6 and Hsp70 cooperate
to suppress <italic toggle="yes">&#x003b1;</italic>-synuclein aggregation</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>9039</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-08324-z</pub-id><pub-id pub-id-type="pmid">28831037</pub-id>
</element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name><surname>Folke</surname><given-names>J.</given-names></name><name><surname>Arkan</surname><given-names>S.</given-names></name><name><surname>Martinsson</surname><given-names>I.</given-names></name><name><surname>Aznar</surname><given-names>S.</given-names></name><name><surname>Gouras</surname><given-names>G.</given-names></name><name><surname>Brudek</surname><given-names>T.</given-names></name><name><surname>Hansen</surname><given-names>C.</given-names></name><article-title>DNAJB6b is
Downregulated in Synucleinopathies</article-title><source>J. Parkinson&#x02019;s
Dis.</source><year>2021</year><volume>11</volume><fpage>1791</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.3233/JPD-202512</pub-id><pub-id pub-id-type="pmid">34334418</pub-id>
</element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name><surname>Aslam</surname><given-names>M.</given-names></name><name><surname>Kandasamy</surname><given-names>N.</given-names></name><name><surname>Ullah</surname><given-names>A.</given-names></name><etal/><article-title>Putative second hit
rare genetic variants in families with seemingly GBA-associated Parkinson&#x02019;s
disease</article-title><source>npj Genomic Med.</source><year>2021</year><volume>6</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1038/s41525-020-00163-8</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name><surname>&#x000d6;sterlund</surname><given-names>N.</given-names></name><name><surname>Lundqvist</surname><given-names>M.</given-names></name><name><surname>Ilag</surname><given-names>L. L.</given-names></name><name><surname>Gr&#x000e4;slund</surname><given-names>A.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><article-title>Amyloid-<italic toggle="yes">&#x003b2;</italic> oligomers are captured
by the DNAJB6 chaperone: Direct detection of interactions that can
prevent primary nucleation</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>8135</fpage><lpage>8144</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013459</pub-id><pub-id pub-id-type="pmid">32350108</pub-id>
</element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name><surname>Udan-Johns</surname><given-names>M.</given-names></name><name><surname>Bengoechea</surname><given-names>R.</given-names></name><name><surname>Bell</surname><given-names>S.</given-names></name><name><surname>Shao</surname><given-names>J.</given-names></name><name><surname>Diamond</surname><given-names>M. I.</given-names></name><name><surname>True</surname><given-names>H. L.</given-names></name><name><surname>Weihl</surname><given-names>C. C.</given-names></name><name><surname>Baloh</surname><given-names>R. H.</given-names></name><article-title>Prion-like nuclear
aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones</article-title><source>Hum. Mol. Genet.</source><year>2014</year><volume>23</volume><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt408</pub-id><pub-id pub-id-type="pmid">23962724</pub-id>
</element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name><surname>Carlsson</surname><given-names>A.</given-names></name><name><surname>Olsson</surname><given-names>U.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>On the micelle formation of DNAJB6b</article-title><source>QRB Discovery</source><year>2023</year><volume>4</volume><elocation-id>e6</elocation-id><pub-id pub-id-type="doi">10.1017/qrd.2023.4</pub-id><pub-id pub-id-type="pmid">37593255</pub-id>
</element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name><surname>Karamanos</surname><given-names>T. K.</given-names></name><name><surname>Tugarinov</surname><given-names>V.</given-names></name><name><surname>Clore</surname><given-names>G. M.</given-names></name><article-title>Unraveling the structure and dynamics
of the human DNAJB6b chaperone by NMR reveals insights into Hsp40-mediated
proteostasis</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2019</year><volume>116</volume><fpage>21529</fpage><lpage>21538</lpage><pub-id pub-id-type="doi">10.1073/pnas.1914999116</pub-id><pub-id pub-id-type="pmid">31591220</pub-id>
</element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name><surname>Jumper</surname><given-names>J.</given-names></name><name><surname>Evans</surname><given-names>R.</given-names></name><name><surname>Pritzel</surname><given-names>A.</given-names></name><etal/><article-title>Highly accurate protein
structure prediction with AlphaFold</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id>
</element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name><surname>Kakkar</surname><given-names>V.</given-names></name><name><surname>M&#x000e5;nsson</surname><given-names>C.</given-names></name><name><surname>de Mattos</surname><given-names>E.</given-names></name><etal/><article-title>The S/T-Rich Motif in
the DNAJB6 Chaperone Delays Polyglutamine Aggregation and the Onset
of Disease in a Mouse Model</article-title><source>Mol. Cell</source><year>2016</year><volume>62</volume><fpage>272</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.017</pub-id><pub-id pub-id-type="pmid">27151442</pub-id>
</element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name><surname>Carlsson</surname><given-names>A.</given-names></name><name><surname>Axell</surname><given-names>E.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><name><surname>Olsson</surname><given-names>U.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>The Ability
of DNAJB6b to Suppress Amyloid Formation Depends on the Chaperone
Aggregation State</article-title><source>ACS Chem. Neurosci.</source><year>2024</year><volume>15</volume><fpage>1732</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.4c00120</pub-id><pub-id pub-id-type="pmid">38640082</pub-id>
</element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name><surname>Arosio</surname><given-names>P.</given-names></name><name><surname>Michaels</surname><given-names>T. C.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>M&#x000e5;nsson</surname><given-names>C.</given-names></name><name><surname>Emanuelsson</surname><given-names>C.</given-names></name><name><surname>Presto</surname><given-names>J.</given-names></name><name><surname>Johansson</surname><given-names>J.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><article-title>Kinetic analysis
reveals the diversity of microscopic mechanisms through which molecular
chaperones suppress amyloid formation</article-title><source>Nat.
Commun.</source><year>2016</year><volume>7</volume><elocation-id>10948</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10948</pub-id><pub-id pub-id-type="pmid">27009901</pub-id>
</element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name><surname>Shammas</surname><given-names>S. L.</given-names></name><name><surname>Waudby</surname><given-names>C. A.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Buell</surname><given-names>A. K.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Ecroyd</surname><given-names>H.</given-names></name><name><surname>Welland</surname><given-names>M. E.</given-names></name><name><surname>Carver</surname><given-names>J. A.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><name><surname>Meehan</surname><given-names>S.</given-names></name><article-title>Binding of the molecular chaperone <italic toggle="yes">&#x003b1;</italic>b-Crystallin to A<italic toggle="yes">&#x003b2;</italic> amyloid
fibrils inhibits
fibril elongation</article-title><source>Biophys. J.</source><year>2011</year><volume>101</volume><fpage>1681</fpage><lpage>1689</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2011.07.056</pub-id><pub-id pub-id-type="pmid">21961594</pub-id>
</element-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name><surname>Cohen</surname><given-names>S. I. A.</given-names></name><name><surname>Arosio</surname><given-names>P.</given-names></name><name><surname>Presto</surname><given-names>J.</given-names></name><name><surname>Kurudenkandy</surname><given-names>F. R.</given-names></name><name><surname>Biverst&#x000e5;l</surname><given-names>H.</given-names></name><name><surname>Dolfe</surname><given-names>L.</given-names></name><name><surname>Dunning</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Frohm</surname><given-names>B.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><name><surname>Johansson</surname><given-names>J.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><name><surname>Fisahn</surname><given-names>A.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>A molecular
chaperone breaks the catalytic cycle that generates toxic A<italic toggle="yes">&#x003b2;</italic> oligomers</article-title><source>Nat. Struct. Mol.
Biol.</source><year>2015</year><volume>22</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2971</pub-id><pub-id pub-id-type="pmid">25686087</pub-id>
</element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name><surname>Tuttle</surname><given-names>M.
D.</given-names></name><name><surname>Comellas</surname><given-names>G.</given-names></name><name><surname>Nieuwkoop</surname><given-names>A. J.</given-names></name><etal/><article-title>Solid-state NMR structure
of a pathogenic fibril of full-length human <italic toggle="yes">&#x003b1;</italic>-synuclein</article-title><source>Nat. Struct. Mol. Biol.</source><year>2016</year><volume>23</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3194</pub-id><pub-id pub-id-type="pmid">27018801</pub-id>
</element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name><surname>Studier</surname><given-names>F. W.</given-names></name><article-title>Protein
production by auto-induction in high density shaking cultures</article-title><source>Protein Expression Purif.</source><year>2005</year><volume>41</volume><fpage>207</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2005.01.016</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>High-Efficiency
Expression and Purification of DNAJB6b Based on the pH-Modulation
of Solubility and Denaturant-Modulation of Size</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>418</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27020418</pub-id><pub-id pub-id-type="pmid">35056736</pub-id>
</element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name><surname>Hwang</surname><given-names>T.</given-names></name><name><surname>Shaka</surname><given-names>A.</given-names></name><article-title>Water Suppression That Works. Excitation
Sculpting Using Arbitrary
Wave-Forms and Pulsed-Field Gradients</article-title><source>J. Magn.
Reson., Ser. A</source><year>1995</year><volume>112</volume><fpage>275</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1006/jmra.1995.1047</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name><surname>Adams</surname><given-names>R. W.</given-names></name><name><surname>Holroyd</surname><given-names>C. M.</given-names></name><name><surname>Aguilar</surname><given-names>J. A.</given-names></name><name><surname>Nilsson</surname><given-names>M.</given-names></name><name><surname>Morris</surname><given-names>G. A.</given-names></name><article-title>&#x0201c;Perfecting&#x0201d;
WATERGATE: Clean proton NMR spectra from aqueous solution</article-title><source>Chem. Commun.</source><year>2013</year><volume>49</volume><fpage>358</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1039/C2CC37579F</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name><surname>Palmer</surname><given-names>A. G.</given-names></name><name><surname>Cavanagh</surname><given-names>J.</given-names></name><name><surname>Wright</surname><given-names>P. E.</given-names></name><name><surname>Rance</surname><given-names>M.</given-names></name><article-title>Sensitivity improvement
in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy</article-title><source>J. Magn. Reson.</source><year>1991</year><volume>93</volume><fpage>151</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/0022-2364(91)90036-S</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name><surname>Axell</surname><given-names>E.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Lindberg</surname><given-names>M.</given-names></name><name><surname>Dear</surname><given-names>A. J.</given-names></name><name><surname>Ortigosa-Pascual</surname><given-names>L.</given-names></name><name><surname>Andrzejewska</surname><given-names>E. A.</given-names></name><name><surname>&#x00160;neideriene</surname><given-names>G.</given-names></name><name><surname>Thacker</surname><given-names>D.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Sparr</surname><given-names>E.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>The role of
shear forces in primary
and secondary nucleation of amyloid fibrils</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2024</year><volume>121</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1073/pnas.2322572121</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name><surname>Nozaki</surname><given-names>Y.</given-names></name><name><surname>Tanford</surname><given-names>C.</given-names></name><article-title>Examination of titration
behavior</article-title><source>Methods Enzymol.</source><year>1967</year><volume>11</volume><fpage>715</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(67)11088-4</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name><surname>Grey</surname><given-names>M.</given-names></name><name><surname>Dunning</surname><given-names>C. J.</given-names></name><name><surname>Gaspar</surname><given-names>R.</given-names></name><name><surname>Grey</surname><given-names>C.</given-names></name><name><surname>Brundin</surname><given-names>P.</given-names></name><name><surname>Sparr</surname><given-names>E.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><article-title>Acceleration
of <italic toggle="yes">&#x003b1;</italic>-synuclein aggregation by exosomes</article-title><source>J. Biol.
Chem.</source><year>2015</year><volume>290</volume><fpage>2969</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.585703</pub-id><pub-id pub-id-type="pmid">25425650</pub-id>
</element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Sormanni</surname><given-names>P.</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>D. J.</given-names></name><article-title>An aggregation inhibitor specific
to oligomeric intermediates of A<italic toggle="yes">&#x003b2;</italic>42 derived
from phage display libraries of stable, small proteins</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2022</year><volume>119</volume><elocation-id>e2121966119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2121966119</pub-id><pub-id pub-id-type="pmid">35580187</pub-id>
</element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name><surname>Chia</surname><given-names>S.</given-names></name><name><surname>Faidon Brotzakis</surname><given-names>Z.</given-names></name><name><surname>Horne</surname><given-names>R. I.</given-names></name><name><surname>Possenti</surname><given-names>A.</given-names></name><name><surname>Mannini</surname><given-names>B.</given-names></name><name><surname>Cataldi</surname><given-names>R.</given-names></name><name><surname>Nowinska</surname><given-names>M.</given-names></name><name><surname>Staats</surname><given-names>R.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Habchi</surname><given-names>J.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><article-title>Structure-Based
Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation
of <italic toggle="yes">&#x003b1;</italic>-Synuclein Aggregates</article-title><source>Mol. Pharmaceutics</source><year>2023</year><volume>20</volume><fpage>183</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.2c00548</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name><surname>Habchi</surname><given-names>J.</given-names></name><name><surname>Chia</surname><given-names>S.</given-names></name><name><surname>Limbocker</surname><given-names>R.</given-names></name><name><surname>Mannini</surname><given-names>B.</given-names></name><name><surname>Ahn</surname><given-names>M.</given-names></name><name><surname>Perni</surname><given-names>M.</given-names></name><name><surname>Hansson</surname><given-names>O.</given-names></name><name><surname>Arosio</surname><given-names>P.</given-names></name><name><surname>Kumita</surname><given-names>J. R.</given-names></name><name><surname>Challa</surname><given-names>P. K.</given-names></name><name><surname>Cohen</surname><given-names>S. I.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Dobson</surname><given-names>C. M.</given-names></name><name><surname>Knowles</surname><given-names>T. P.</given-names></name><name><surname>Vendruscolo</surname><given-names>M.</given-names></name><article-title>Systematic
development of small molecules
to inhibit specific microscopic steps of A<italic toggle="yes">&#x003b2;</italic>42 aggregation in Alzheimer&#x02019;s disease</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2017</year><volume>114</volume><fpage>E200</fpage><lpage>E208</lpage><pub-id pub-id-type="doi">10.1073/pnas.1615613114</pub-id><pub-id pub-id-type="pmid">28011763</pub-id>
</element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name><surname>T&#x000f6;rner</surname><given-names>R.</given-names></name><name><surname>Kupreichyk</surname><given-names>T.</given-names></name><name><surname>Gremer</surname><given-names>L.</given-names></name><name><surname>Debled</surname><given-names>E. C.</given-names></name><name><surname>Fenel</surname><given-names>D.</given-names></name><name><surname>Schemmert</surname><given-names>S.</given-names></name><name><surname>Gans</surname><given-names>P.</given-names></name><name><surname>Willbold</surname><given-names>D.</given-names></name><name><surname>Schoehn</surname><given-names>G.</given-names></name><name><surname>Hoyer</surname><given-names>W.</given-names></name><name><surname>Boisbouvier</surname><given-names>J.</given-names></name><article-title>Structural basis for the inhibition
of IAPP fibril formation by the co-chaperonin prefoldin</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><elocation-id>2363</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-30042-y</pub-id><pub-id pub-id-type="pmid">35501361</pub-id>
</element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name><surname>Gaspar</surname><given-names>R.</given-names></name><name><surname>Garting</surname><given-names>T.</given-names></name><name><surname>Stradner</surname><given-names>A.</given-names></name><article-title>Eye lens Crystallin
proteins inhibit
the autocatalytic amyloid amplification nature of mature <italic toggle="yes">&#x003b1;</italic>-synuclein fibrils</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><elocation-id>e0235198</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0235198</pub-id><pub-id pub-id-type="pmid">32598365</pub-id>
</element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name><surname>P&#x000e1;lmad&#x000f3;ttir</surname><given-names>T.</given-names></name><name><surname>Waudby</surname><given-names>C. A.</given-names></name><name><surname>Bernfur</surname><given-names>K.</given-names></name><name><surname>Christodoulou</surname><given-names>J.</given-names></name><name><surname>Linse</surname><given-names>S.</given-names></name><name><surname>Malmendal</surname><given-names>A.</given-names></name><article-title>Morphology-Dependent
Interactions
between <italic toggle="yes">&#x003b1;</italic>-Synuclein Monomers and Fibrils</article-title><source>Int. J Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>5191</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24065191</pub-id><pub-id pub-id-type="pmid">36982264</pub-id>
</element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name><surname>Heesink</surname><given-names>G.</given-names></name><name><surname>van den Oetelaar</surname><given-names>M. C.</given-names></name><name><surname>Semerdzhiev</surname><given-names>S. A.</given-names></name><name><surname>Ottmann</surname><given-names>C.</given-names></name><name><surname>Brunsveld</surname><given-names>L.</given-names></name><name><surname>Blum</surname><given-names>C.</given-names></name><name><surname>Claessens</surname><given-names>M. M.</given-names></name><article-title>14&#x02013;3-3<italic toggle="yes">&#x003c4;</italic> as a Modulator of Early <italic toggle="yes">&#x003b1;</italic>-Synuclein Multimerization
and Amyloid Formation</article-title><source>ACS Chem. Neurosci.</source><year>2024</year><volume>15</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.4c00100</pub-id><pub-id pub-id-type="pmid">38635928</pub-id>
</element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name><surname>Schartman</surname><given-names>R. R.</given-names></name><article-title>On the
thermodynamics of cocrystal formation</article-title><source>Int.
J. Pharm.</source><year>2009</year><volume>365</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2008.08.029</pub-id><pub-id pub-id-type="pmid">18804155</pub-id>
</element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Rasmuson</surname><given-names>C.</given-names></name><article-title>Thermodynamics and crystallization of the theophylline-glutaric
acid cocrystal</article-title><source>Cryst. Growth Des.</source><year>2013</year><volume>13</volume><fpage>1153</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1021/cg3014859</pub-id></element-citation></ref></ref-list></back></article><!--Stylesheet Name and Version:openaccess.xsl v2.1
Date and Time: 2025-05-23T06:27:13.424-04:00
XML Format:jats-->